Antigen binding protein targeting PD-L1 and CD40 as well as preparation and application thereof
Patent Information
- Application Number
- CN202380030975.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-04-02
- Filing Date
- 2023-03-31
- Publication Date
- 2024-11-22
AI Technical Summary
Existing antigen-binding protein drugs targeting PD-L1 and CD40 have limited efficacy, poor safety profiles, and a small therapeutic window in clinical applications.
Develop a bispecific antigen-binding protein targeting PD-L1 and CD40. By blocking the PD-1/PD-L1 inhibitory signaling pathway and activating the CD40 receptor, it can activate antigen-presenting cells and lymphocytes, achieving a synergistic anti-tumor effect in the tumor microenvironment while reducing systemic drug toxicity.
It significantly improved the efficacy of anti-tumor drugs, broadened the therapeutic window, reduced systemic side effects, and provided a safer treatment option.
Smart Images

Figure 00000055_0000 
Figure 00000055_0001 
Figure 00000056_0000
Abstract
Description
Antigen binding proteins targeting PD-L1 and CD40 and their preparation and application
[0001] This application claims priority to Chinese patent application No. 202210351186X, filed April 2, 2022. This application incorporates the entire text of the aforementioned Chinese patent application. Technical Field
[0002] The present invention relates to the field of biopharmaceuticals, and in particular to a bispecific antigen-binding protein targeting PD-L1 and CD40, and its preparation and application. Background Art
[0003] CD40 is a glycosylated type I transmembrane protein and a member of the tumor necrosis factor receptor superfamily (TNFRSF), also known as tumor necrosis factor receptor superfamily member 5 (TNFRSF5). CD40 is expressed on the surface of a range of antigen-presenting cells (APCs), including monocytes, dendritic cells (DCs), B cells, and macrophages. Its ligand, CD40L, is primarily expressed on the surface of lymphocytes, including T cells, B cells, and NK cells, typically existing in trimer and multimer forms. CD40 and CD40L are a pair of co-stimulatory molecules. Activation of CD40 downstream signaling pathways requires cross-linking of CD40 by trimer and multimer forms of CD40L. They interact on the cell surface, causing CD40 to redistribute to membrane lipid rafts and undergo conformational changes. CD40 recruits TNFR-associated factors (TRAFs) in the cytoplasm through its intracellular terminal domain to promote intracellular signal transduction, thereby activating different signaling pathways, such as the canonical and non-canonical nuclear factor κB pathways, p38 mitogen-activated protein kinase, phosphatidylinositol-3 kinase (PI3K), and phospholipase Cγ pathways. Through the genes targeted by these signaling pathways, they further regulate cell apoptosis, cell cycle progression, cytokine production, and the expression of cell surface immune regulators. Therefore, activating CD40 can increase antigen presentation, promote cytokine secretion, activate lymphocytes, and simultaneously stimulate and activate the human innate and adaptive immune systems, producing a synergistic effect to resist the occurrence and development of cancer.
[0004] CD40 is also widely expressed on tumor cells. It is expressed in nearly all B-cell malignancies and a wide range of solid tumors, including melanoma, lung cancer, breast cancer, colon cancer, prostate cancer, pancreatic cancer, kidney cancer, ovarian cancer, and head and neck cancer. CD40 expressed on the surface of tumor cells can mediate tumor cell death. In the absence of immune helper cells, cross-linking CD40 expressed on the surface of various tumor cells through CD40L can mediate direct cytotoxicity. In vitro, cross-linking of CD40 through CD40L has been shown to induce tumor cell apoptosis and inhibit the growth of solid tumor cells and B-cell malignancies. In vivo, activation of CD40 also mediates tumor suppression. Evidence shows that in immunodeficient mice, interfering with CD40 on the surface of tumor cells through CD40L inhibits the growth of breast cancer cell xenografts or B lymphocyte xenografts, even in the absence of lymphocyte activation.
[0005] Therefore, the mechanism of CD40-mediated tumor cell death can be dual: stimulating the immune system to kill tumor cells and directly cytotoxic to tumor cells, resulting in a synergistic anti-tumor effect. Agonistic anti-CD40 antibodies, similar to CD40L, can cross-link and activate CD40 on the surface of immune cells and tumor cells, exerting a significant anti-tumor effect. This anti-tumor effect has been demonstrated in preclinical animal models and clinical cancer patient trials, and can be combined with chemotherapy drugs such as gemcitabine and paclitaxel, as well as with immunomodulatory drugs such as PD-1 and CTLA-4 antibodies, to produce a synergistic anti-tumor effect.
[0006] Currently, nearly 20 CD40 antibody drugs are in clinical trials for cancer treatment, but the earliest product is only in Phase II clinical trials, and no products have yet been marketed. The main challenges facing CD40 antibodies in clinical practice include low objective response rates, significant toxicity, and a low tolerable dose. These results may be due to weak agonist activity, such as Celldex's product CDX-1140. In its Phase I clinical trial, no complete or partial response was achieved in 42 patients treated with monotherapy; only one of 20 patients achieved a partial response when treated with rhFLT3L. This product exhibits weak in vitro activation of DCs, and its agonist activity is not enhanced when cross-linked. This is also due to the lack of selective activation of CD40 antibodies, which can lead to systemic toxicity. For example, Roche's CD40 antibody Selicrelumab caused significant cytokine release syndrome and liver toxicity in some patients in clinical trials when the dose exceeded 0.2 mg / kg; Apexigen's CD40 antibody APX005M caused significant neutropenia, as well as further sepsis and septic shock in some patients in clinical trials when the dose exceeded 0.3 mg / kg. In summary, current clinical CD40 antibodies face the problem and challenge of a narrow therapeutic window between effectiveness and safety. Therefore, the development of other CD40 antibodies will provide the possibility of treating a variety of tumors and has high scientific and market value.
[0007] PD-L1, or programmed death ligand 1, also known as CD274 and B7H1, is a glycosylated type I transmembrane protein and one of the ligands for PD-1 (programmed death protein 1). Under normal circumstances, PD-L1 is widely expressed on antigen-presenting cells, such as dendritic cells, macrophages, and B cells, as well as other immune cells. When PD-L1 binds to the PD-1 receptor expressed on the surface of T cells, it inhibits T cell activation and cytokine secretion, playing a key role in inducing immune contraction and maintaining immune tolerance. PD-L1 is also abundantly expressed on the surface of many cancer cells, including renal cell carcinoma, breast cancer, colorectal cancer, gastric cancer, non-small cell lung cancer, papillary thyroid carcinoma, and testicular cancer. The binding of PD-L1 on tumor cells to PD-1 on tumor-infiltrating T cells (TILs) activates Src homology region 2 domain-containing phosphatases (SHPs), leading to inhibition of the T cell receptor (TCR) pathway and suppression of T cell activity. In addition, tumor cells interrupt immune surveillance and promote cancer cell survival by utilizing the PD-L1 / PD-1 signaling pathway.
[0008] Therefore, blocking the PD-L1 / PD-1 signaling axis through antibodies can reactivate immune cells such as T cells that are suppressed and exhausted in the tumor microenvironment, and through them eliminate cancer cells and re-establish immune balance. Based on the above findings, therapeutic PD-L1 antibodies (e.g., atezolizumab, avelumab, and durvalumab) and PD-1 antibodies (e.g., nivolumab, pembrolizumab, and cemiplimab) have been developed and marketed, and have achieved clinical responses of 10%-40% for a variety of cancers, including melanoma, small cell lung cancer, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and Merkel cell carcinoma.
[0009] However, while anti-PD-L1 / PD-1 therapy has demonstrated impressive efficacy in cancer treatment, particularly in solid tumors, sustained responses occur in only a small subset of patients. Some patients who initially respond to treatment ultimately develop acquired resistance. Meanwhile, a significant number of patients remain unresponsive to anti-PD-L1 / PD-1 therapy, a phenomenon known as primary resistance. Therefore, the development of more effective immunotherapies that can synergize with anti-PD-L1 / PD-1 therapy to overcome both primary and acquired resistance is urgently needed, and this area has become a key focus of current cancer immunotherapy efforts.
[0010] Currently, there are no antigen-binding proteins targeting both PD-L1 and CD40 on the market, and the market has a great demand for antigen-binding proteins that simultaneously target both PD-L1 and CD40.
[0011] Summary of the Invention
[0012] In response to the technical defects of antigen-binding proteins targeting PD-L1 and CD40 in the prior art, which have limited efficacy and poor safety, the present invention provides antigen-binding proteins targeting PD-L1 and CD40, as well as their preparation and application. The antigen-binding proteins targeting PD-L1 and CD40 achieve significant synergistic anti-tumor effects by blocking the PD-1 / PD-L1 inhibitory signaling pathway and acting on the activating CD40 receptor, while simultaneously activating antigen-presenting cells and lymphocytes. Furthermore, the activation of immune cells by the antigen-binding proteins targeting PD-L1 and CD40 occurs only in the tumor microenvironment, significantly eliminating systemic drug toxicity and side effects. This allows the antigen-binding proteins targeting PD-L1 and CD40 to exert their excellent anti-tumor efficacy under very safe conditions.
[0013] To solve the above technical problems, the first aspect of the present invention provides an antigen binding protein targeting PD-L1 and CD40, which comprises a first protein functional region and a second protein functional region, wherein the first protein functional region comprises an antigen binding protein targeting CD40, and the second protein functional region comprises an antigen binding protein targeting PD-L1; wherein,
[0014] The antigen binding protein targeting CD40 comprises a light chain variable region (VL) and a heavy chain variable region (VH), the VL comprising LCDR1, LCDR2 and LCDR3, the VH comprising HCDR1, HCDR2 and HCDR3; the LCDR1 comprises the amino acid sequence as shown in SEQ ID NO:38 or variant 1 having 3, 2 or 1 amino acid mutations in SEQ ID NO:38, the LCDR2 comprises the amino acid sequence as shown in SEQ ID NO:43 or variant 2 having 3, 2 or 1 amino acid mutations in SEQ ID NO:43, the LCDR3 comprises the amino acid sequence as shown in SEQ ID NO:48 or variant 3 having 3, 2 or 1 amino acid mutations in SEQ ID NO:48; the HCDR1 comprises the amino acid sequence as shown in SEQ ID NO:8 or variant 4 having 3, 2 or 1 amino acid mutations in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence as shown in SEQ ID NO:18 or variant 5 having 3, 2 or 1 amino acid mutations in SEQ ID NO:18, and the HCDR3 comprises the amino acid sequence as shown in SEQ ID NO: The amino acid sequence shown in NO:27 or variant 6 having 3, 2 or 1 amino acid mutations in SEQ ID NO:27.
[0015] In some technical solutions of the present invention, the antigen-binding protein targeting CD40 comprises a light chain variable region (VL) and a heavy chain variable region (VH), the VL comprises LCDR1, LCDR2 and LCDR3, and the VH comprises HCDR1, HCDR2 and HCDR3; the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:38, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:43, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:48 or a variant 3 having 3, 2 or 1 amino acid mutations in SEQ ID NO:48; the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:18, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:27.
[0016] In some technical solutions of the present invention, the variant 3 comprises an amino acid sequence having a PTM site mutation in the amino acid sequence of SEQ ID NO: 48, preferably comprising an amino acid sequence having an amino acid mutation at position 4 and / or 5 of the amino acid sequence of SEQ ID NO: 48, wherein the amino acid mutation is preferably an amino acid substitution, more preferably a conservative amino acid substitution. Preferably, the variant 3 is an amino acid sequence having N4A / F / Y / V / N and / or S5N mutations in the amino acid sequence of SEQ ID NO: 48. More preferably, the variant 3 is an amino acid sequence as shown in any one of SEQ ID NOs: 49-53.
[0017] In some technical solutions of the present invention, in the antigen-binding protein targeting CD40, the LCDR1 includes the amino acid sequence shown in SEQ ID NO:38, the LCDR2 includes the amino acid sequence shown in SEQ ID NO:43, and the LCDR3 includes the amino acid sequence 3 shown in any one of SEQ ID NOs:48-53; the HCDR1 includes the amino acid sequence shown in SEQ ID NO:8, the HCDR2 includes the amino acid sequence shown in SEQ ID NO:18, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO:27. Specific CDR combinations are shown in Table 1-1.
[0018] Table 1-1 Specific CDR combinations of antigen binding proteins targeting CD40
[0019] In some technical solutions of the present invention, in the antigen-binding protein targeting CD40, the VL comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence that is at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 68, and the VH comprises the amino acid sequence of SEQ ID NO: 60, or an amino acid sequence that is at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 60. More preferably, the VL comprises the amino acid sequence of any one of SEQ ID NOs: 68-73, and the VH comprises the amino acid sequence of SEQ ID NO: 60. Specific VL and VH combinations are shown in Tables 1-2.
[0020] Table 1-2 Specific VL and VH combinations of antigen binding proteins targeting CD40
[0021] In some technical schemes of the present invention, the antigen binding protein targeting CD40 is a full-length antibody, which comprises a light chain and a heavy chain; the light chain comprises a light chain constant region (CL), which is preferably a human antibody light chain constant region, and the human antibody light chain constant region is more preferably a κ subtype light chain constant region; the heavy chain comprises a heavy chain constant region (CH), which is preferably a human antibody heavy chain constant region, more preferably a hIgG1, hIgG2, hIgG3 or hIgG4 subtype heavy chain constant region, and further preferably a hIgG1 subtype heavy chain constant region.
[0022] In some technical solutions of the present invention, the antigen-binding protein targeting CD40 is a full-length antibody, comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 87-92, and the heavy chain comprises the amino acid sequence set forth in SEQ ID NOs: 78 or 84. Preferably, the light chain comprises the amino acid sequence set forth in SEQ ID NO: 87, and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 78; or, the light chain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 88-92, and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 84. Specific light chain and heavy chain combinations are shown in Tables 1-3.
[0023] Table 1-3 Specific light chain and heavy chain combinations of antigen binding proteins targeting CD40
[0024] In some technical solutions of the present invention, the antigen binding protein targeting PD-L1 comprises a heavy chain variable region (VH), wherein the VH comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises the amino acid sequence as shown in SEQ ID NO: 5 or a variant 7 having 3, 2 or 1 amino acid mutations in SEQ ID NO: 5, the HCDR2 comprises the amino acid sequence as shown in SEQ ID NO: 16 or a variant 8 having 3, 2 or 1 amino acid mutations in SEQ ID NO: 16, and the HCDR3 comprises the amino acid sequence as shown in SEQ ID NO: 25 or a variant 9 having 3, 2 or 1 amino acid mutations in SEQ ID NO: 25.
[0025] In some technical solutions of the present invention, variant 7 is an amino acid sequence having an amino acid mutation at position 3 and / or 6 of SEQ ID NO: 5, variant 8 is an amino acid sequence having an amino acid mutation at position 1, 3 and / or 6 of SEQ ID NO: 16, and variant 9 is an amino acid sequence having an amino acid mutation at position 4, 8 and / or 11 of SEQ ID NO: 25, wherein the amino acid mutation is preferably an amino acid substitution, more preferably a conservative amino acid substitution. More preferably, variant 7 is an amino acid sequence having an N3T / D and / or N5S mutation in SEQ ID NO: 5, variant 8 is an amino acid sequence having a W1R, D3T and / or K5E mutation in SEQ ID NO: 16, and variant 9 is an amino acid sequence having an I4L, V8I and / or A11D mutation in SEQ ID NO: 25. Preferably, the variant 7 is the amino acid sequence shown in SEQ ID NO: 7 or 9, the variant 8 is the amino acid sequence shown in SEQ ID NO: 19, and the variant 9 is the amino acid sequence shown in SEQ ID NO: 28, 29 or 30.
[0026] In some technical solutions of the present invention, in the antigen-binding protein targeting PD-L1, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 5, 7 or 9, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 16 or 19, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 25, 28, 29 or 30.
[0027] In some technical solutions of the present invention, in the antigen-binding protein targeting PD-L1, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 5, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 16, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 25; or, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 7, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 16, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 25; or, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 7, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 19, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 28; or, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 9, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 19, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 25; or, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 9, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 19, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 25. NO:19, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:29; or, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:9, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:19, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:30; or, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:9, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:19, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:28.
[0028] In some technical solutions of the present invention, in the antigen-binding protein targeting PD-L1, the VH comprises the amino acid sequence as shown in SEQ ID NO: 57, or an amino acid sequence that is at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 57. More preferably, the VH comprises the amino acid sequence as shown in any one of SEQ ID NOs: 57-65.
[0029] In some technical solutions of the present invention, the first protein functional region is an immunoglobulin including the antigen binding protein targeting CD40, and the second protein functional region includes one, two or more VHs of the antigen binding protein targeting PD-L1.
[0030] In some technical solutions of the present invention, the VH of the antigen-binding protein targeting PD-L1 is directly linked to the immunoglobulin; or, the VH is linked to the immunoglobulin through a linker; or, when the number of the VH is greater than 1, each VH can be directly or through a linker to the immunoglobulin.
[0031] In some technical solutions of the present invention, when the VH is connected to the immunoglobulin via a linker, the linker is selected from GS, GGS and any one of the amino acid sequences shown in SEQ ID NOs: 100-106.
[0032] In some technical solutions of the present invention, the second protein functional region comprises two VHs of the antigen-binding protein targeting PD-L1. Preferably, the two VHs comprised in the second protein functional region are identical; and / or the C-termini of the two VHs are connected to the N-termini of the two heavy chains in the immunoglobulin via a linker such as GGS or SEQ ID NO: 5.
[0033] In some technical schemes of the present invention, the first protein functional region comprises two light chains including the amino acid sequence shown in any one of SEQ ID NOs: 88-92 and two heavy chains including the amino acid sequence shown in SEQ ID NO: 84, and the second protein functional region comprises two VHs including the amino acid sequence shown in any one of SEQ ID NOs: 79-83, and the two VHs are respectively connected to the N-termini of the two heavy chains in the first protein functional region through a linker such as GGS or SEQ ID NO: 5 at their C-termini.
[0034] Preferably, the antigen binding protein targeting PD-L1 and CD40 comprises a first polypeptide chain and a second polypeptide chain as shown below:
[0035] The second polypeptide chain of SEQ ID NO:89 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:94; or the second polypeptide chain of SEQ ID NO:91 and the first polypeptide chain of SEQ ID NO:94; or the second polypeptide chain of SEQ ID NO:90 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:92 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:95; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:96; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:97; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:98; NO:91, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:95; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:93; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:96; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:89, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:97; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:90, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:97; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:88, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:98; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:88, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:99; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:98; or The second polypeptide chain shown in NO:91 has an amino acid sequence as the first polypeptide chain shown in SEQ ID NO:99.
[0036] To solve the above technical problems, the second aspect of the present invention provides an antigen binding protein targeting PD-L1 and CD40, which comprises a first protein functional region and a second protein functional region, wherein the first protein functional region comprises an antigen binding protein targeting CD40, and the second protein functional region comprises an antigen binding protein targeting PD-L1; wherein,
[0037] The antigen binding protein targeting PD-L1 comprises a heavy chain variable region (VH), wherein the VH comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1 comprises the amino acid sequence as shown in SEQ ID NO: 5 or a variant 7 having 3, 2, or 1 amino acid mutations in SEQ ID NO: 5, the HCDR2 comprises the amino acid sequence as shown in SEQ ID NO: 16 or a variant 8 having 3, 2, or 1 amino acid mutations in SEQ ID NO: 16, and the HCDR3 comprises the amino acid sequence as shown in SEQ ID NO: 25 or a variant 9 having 3, 2, or 1 amino acid mutations in SEQ ID NO: 25.
[0038] In some technical solutions of the present invention, variant 7 is an amino acid sequence having an amino acid mutation at position 3 and / or 6 of SEQ ID NO: 5, variant 8 is an amino acid sequence having an amino acid mutation at position 1, 3 and / or 6 of SEQ ID NO: 16, and variant 9 is an amino acid sequence having an amino acid mutation at position 4, 8 and / or 11 of SEQ ID NO: 25, wherein the amino acid mutation is preferably an amino acid substitution, more preferably a conservative amino acid substitution. More preferably, variant 7 is an amino acid sequence having an N3T / D and / or N5S mutation in SEQ ID NO: 5, variant 8 is an amino acid sequence having a W1R, D3T and / or K5E mutation in SEQ ID NO: 16, and variant 9 is an amino acid sequence having an I4L, V8I and / or A11D mutation in SEQ ID NO: 25. Preferably, the variant 7 is the amino acid sequence shown in SEQ ID NO: 7 or 9, the variant 8 is the amino acid sequence shown in SEQ ID NO: 19, and the variant 9 is the amino acid sequence shown in SEQ ID NO: 28, 29 or 30.
[0039] In some technical solutions of the present invention, in the antigen-binding protein targeting PD-L1, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 5, 7 or 9, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 16 or 19, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 25, 28, 29 or 30.
[0040] In some technical solutions of the present invention, in the antigen-binding protein targeting PD-L1, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 5, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 16, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 25; or, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 7, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 16, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 25; or, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 7, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 19, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 28; or, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 9, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 19, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 25; or, the HCDR1 includes the amino acid sequence shown in SEQ ID NO: 9, the HCDR2 includes the amino acid sequence shown in SEQ ID NO: 19, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO: 25. NO:19, the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:29; or, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:9, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:19, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:30; or, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:9, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:19, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:28.
[0041] In some technical solutions of the present invention, in the antigen-binding protein targeting PD-L1, the VH comprises the amino acid sequence as shown in SEQ ID NO: 57, or an amino acid sequence that is at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 57. More preferably, the VH comprises the amino acid sequence as shown in any one of SEQ ID NOs: 57-65.
[0042] In some technical solutions of the present invention, the antigen-binding protein targeting CD40 comprises a light chain variable region (VL) and a heavy chain variable region (VH), the VL comprises LCDR1, LCDR2 and LCDR3, the VH comprises HCDR1, HCDR2 and HCDR3; the LCDR1 comprises the amino acid sequence as shown in SEQ ID NO:38 or variant 1 having 3, 2 or 1 amino acid mutations in SEQ ID NO:38, the LCDR2 comprises the amino acid sequence as shown in SEQ ID NO:43 or variant 2 having 3, 2 or 1 amino acid mutations in SEQ ID NO:43, the LCDR3 comprises the amino acid sequence as shown in SEQ ID NO:48 or variant 3 having 3, 2 or 1 amino acid mutations in SEQ ID NO:48; the HCDR1 comprises the amino acid sequence as shown in SEQ ID NO:8 or variant 4 having 3, 2 or 1 amino acid mutations in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence as shown in SEQ ID NO:18 or variant 1 having 3, 2 or 1 amino acid mutations in SEQ ID NO:18 Variant 5 having 3, 2 or 1 amino acid mutations in NO:18, wherein the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:27 or variant 6 having 3, 2 or 1 amino acid mutations in SEQ ID NO:27.
[0043] In some technical solutions of the present invention, the antigen-binding protein targeting CD40 comprises a light chain variable region (VL) and a heavy chain variable region (VH), the VL comprises LCDR1, LCDR2 and LCDR3, and the VH comprises HCDR1, HCDR2 and HCDR3; the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:38, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:43, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:48 or a variant 3 having 3, 2 or 1 amino acid mutations in SEQ ID NO:48; the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:18, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:27.
[0044] In some technical solutions of the present invention, the variant 3 comprises an amino acid sequence having a PTM site mutation in the amino acid sequence of SEQ ID NO: 48, preferably comprising an amino acid sequence having an amino acid mutation at position 4 and / or 5 of the amino acid sequence of SEQ ID NO: 48, wherein the amino acid mutation is preferably an amino acid substitution, more preferably a conservative amino acid substitution. Preferably, the variant 3 is an amino acid sequence having N4A / F / Y / V / N and / or S5N mutations in the amino acid sequence of SEQ ID NO: 48. More preferably, the variant 3 is an amino acid sequence as shown in any one of SEQ ID NOs: 49-53.
[0045] In some technical solutions of the present invention, in the antigen-binding protein targeting CD40, the LCDR1 includes the amino acid sequence shown in SEQ ID NO:38, the LCDR2 includes the amino acid sequence shown in SEQ ID NO:43, and the LCDR3 includes the amino acid sequence 3 shown in any one of SEQ ID NOs:48-53; the HCDR1 includes the amino acid sequence shown in SEQ ID NO:8, the HCDR2 includes the amino acid sequence shown in SEQ ID NO:18, and the HCDR3 includes the amino acid sequence shown in SEQ ID NO:27. Specific CDR combinations are shown in Table 1-1.
[0046] In some technical solutions of the present invention, in the antigen-binding protein targeting CD40, the VL comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence that is at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 68, and the VH comprises the amino acid sequence of SEQ ID NO: 60, or an amino acid sequence that is at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 60. More preferably, the VL comprises the amino acid sequence of any one of SEQ ID NOs: 68-73, and the VH comprises the amino acid sequence of SEQ ID NO: 60. Specific VL and VH combinations are shown in Tables 1-2.
[0047] In some technical schemes of the present invention, the antigen binding protein targeting CD40 is a full-length antibody, which comprises a light chain and a heavy chain; the light chain comprises a light chain constant region (CL), which is preferably a human antibody light chain constant region, and the human antibody light chain constant region is more preferably a κ subtype light chain constant region; the heavy chain comprises a heavy chain constant region (CH), which is preferably a human antibody heavy chain constant region, more preferably a hIgG1, hIgG2, hIgG3 or hIgG4 subtype heavy chain constant region, and further preferably a hIgG1 subtype heavy chain constant region.
[0048] In some technical solutions of the present invention, the antigen-binding protein targeting CD40 is a full-length antibody, comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 87-92, and the heavy chain comprises the amino acid sequence set forth in SEQ ID NOs: 78 or 84. Preferably, the light chain comprises the amino acid sequence set forth in SEQ ID NO: 87, and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 78; or, the light chain comprises the amino acid sequence set forth in any one of SEQ ID NOs: 88-92, and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO: 84. Specific light chain and heavy chain combinations are shown in Tables 1-3.
[0049] In some technical solutions of the present invention, the first protein functional region is an immunoglobulin including the antigen binding protein targeting CD40, and the second protein functional region includes one, two or more VHs of the antigen binding protein targeting PD-L1.
[0050] In some technical solutions of the present invention, the VH of the antigen-binding protein targeting PD-L1 is directly linked to the immunoglobulin; or, the VH is linked to the immunoglobulin through a linker; or, when the number of the VH is greater than 1, each VH can be directly or through a linker to the immunoglobulin.
[0051] In some technical solutions of the present invention, when the VH is connected to the immunoglobulin via a linker, the linker is selected from GS, GGS and any one of the amino acid sequences shown in SEQ ID NOs: 100-106.
[0052] In some technical solutions of the present invention, the second protein functional region comprises two VHs of the antigen-binding protein targeting PD-L1. Preferably, the two VHs comprised in the second protein functional region are identical; and / or the C-termini of the two VHs are connected to the N-termini of the two heavy chains in the immunoglobulin via a linker such as GGS or SEQ ID NO: 5.
[0053] In some technical schemes of the present invention, the first protein functional region comprises two light chains including the amino acid sequence shown in any one of SEQ ID NOs: 88-92 and two heavy chains including the amino acid sequence shown in SEQ ID NO: 84, and the second protein functional region comprises two VHs including the amino acid sequence shown in any one of SEQ ID NOs: 79-83, and the two VHs are respectively connected to the N-termini of the two heavy chains in the first protein functional region through a linker such as GGS or SEQ ID NO: 5 at their C-termini.
[0054] Preferably, the antigen binding protein targeting PD-L1 and CD40 comprises a first polypeptide chain and a second polypeptide chain as shown below:
[0055] The second polypeptide chain of SEQ ID NO:89 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:94; or the second polypeptide chain of SEQ ID NO:91 and the first polypeptide chain of SEQ ID NO:94; or the second polypeptide chain of SEQ ID NO:90 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:92 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:95; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:96; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:97; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:98; NO:91, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:95; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:93; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:96; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:89, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:97; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:90, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:97; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:88, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:98; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:88, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:99; or, the second polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as set forth in SEQ ID NO:98; or The second polypeptide chain shown in NO:91 has an amino acid sequence as the first polypeptide chain shown in SEQ ID NO:99.
[0056] In the present invention, variant 1, variant 2, variant 3, variant 4, variant 5, variant 6, variant 7, variant 8 and variant 9 are only used to distinguish different variants, the first protein functional region and the second protein functional region are only used to distinguish different protein functions, and the first polypeptide chain and the second polypeptide chain are only used to distinguish different polypeptide chains. The numbers and serial numbers do not represent actual meanings.
[0057] The amino acid sequences of the CDRs in the present invention are determined according to the Chothia definition rules.
[0058] To solve the above technical problems, the present invention provides, on the other hand, a chimeric antigen receptor (CAR), which comprises the antigen binding protein targeting PD-L1 and CD40 as described in the present invention.
[0059] To solve the above technical problems, the present invention provides, on the other hand, an isolated nucleic acid encoding the antigen binding protein targeting PD-L1 and CD40 as described in the present invention.
[0060] To solve the above technical problems, the present invention further provides a recombinant expression vector comprising the isolated nucleic acid according to the present invention. Preferably, the recombinant expression vector comprises a eukaryotic expression vector and / or a prokaryotic expression vector.
[0061] To solve the above technical problems, the present invention further provides a transformant comprising the isolated nucleic acid or the recombinant expression vector described herein. Preferably, the host cell of the transformant is a prokaryotic cell and / or a eukaryotic cell, the prokaryotic cell is preferably an E. coli cell such as TG1 or BL21, and the eukaryotic cell is preferably a HEK293 cell or a CHO cell.
[0062] To solve the above technical problems, the present invention further provides a method for preparing the antigen-binding protein targeting PD-L1 and CD40 as described in the present invention, comprising the following steps: culturing the transformant as described in the present invention, and obtaining the antigen-binding protein targeting PD-L1 and CD40 from the culture.
[0063] To address the above technical issues, the present invention further provides an antibody-drug conjugate (ADC) comprising an antigen-binding protein targeting PD-L1 and CD40 as described herein, and a cytotoxic agent or a label. Preferably, the cytotoxic agent is MMAF or MMAE, and the label is a fluorescent agent.
[0064] To address the above technical problems, the present invention further provides a genetically modified cell that expresses the chimeric antigen receptor described in the present invention. Preferably, the genetically modified cell is a eukaryotic cell, preferably an isolated human cell, and more preferably an immune cell such as a T cell or a NK cell.
[0065] To solve the above technical problems, the present invention provides a pharmaceutical composition on the other hand, which comprises one or more of the antigen binding protein targeting PD-L1 and CD40 as described in the present invention, the chimeric antigen receptor as described in the present invention, the isolated nucleic acid as described in the present invention, the recombinant expression vector as described in the present invention, the genetically modified cell as described in the present invention, and the antibody-drug conjugate as described in the present invention, and / or a pharmaceutically acceptable carrier. Preferably, the pharmaceutical composition further comprises other anti-tumor drugs as active ingredients. The anti-tumor drugs include but are not limited to: chemotherapy drugs, nucleotide drugs, small molecule targeted drugs, monoclonal antibody drugs, bi / multi-specific antibody drugs, recombinant protein drugs, immunomodulatory drugs, cell therapy drugs and gene therapy drugs.
[0066] To solve the above technical problems, the present invention provides a detection reagent on the other hand, which comprises the antigen binding protein targeting PD-L1 and CD40 as described in the present invention and / or the antibody-drug conjugate as described in the present invention. Preferably, the detection reagent is in liquid dosage form, gaseous dosage form, solid dosage form and semi-solid dosage form. More preferably, the detection reagent further comprises a secondary antibody, CD40 or a derivative thereof, the secondary antibody, for example, an anti-human IgG antibody coupled to horseradish peroxidase and an anti-human IgG antibody coupled to biotin protein.
[0067] To solve the above technical problems, the present invention provides a kit of parts, which includes kit A, wherein kit A contains one or more of the antigen binding protein targeting PD-L1 and CD40 as described in the present invention, the chimeric antigen receptor as described in the present invention, the pharmaceutical composition as described in the present invention, the detection reagent as described in the present invention, the genetically modified cells as described in the present invention, and the antibody-drug conjugate as described in the present invention.
[0068] Preferably, the kit further comprises a kit B, which contains other anti-tumor antibodies or pharmaceutical compositions comprising the other anti-tumor antibodies, and / or one or more of a group consisting of hormone preparations, targeted small molecule preparations, proteasome inhibitors, imaging agents, diagnostic agents, chemotherapeutic agents, oncolytic drugs, cytotoxic agents, cytokines, activators of co-stimulatory molecules, inhibitors of inhibitory molecules, and vaccines.
[0069] To solve the above technical problems, the present invention further provides the use of one or more of the antigen binding protein targeting PD-L1 and CD40 as described in the present invention, the chimeric antigen receptor as described in the present invention, the isolated nucleic acid as described in the present invention, the recombinant expression vector as described in the present invention, the pharmaceutical composition as described in the present invention, the detection reagent as described in the present invention, the kit as described in the present invention, the genetically modified cell as described in the present invention, and the antibody-drug conjugate as described in the present invention in the preparation of a drug for diagnosing, preventing and / or treating PD-L1 and / or CD40-related diseases. Preferably, the PD-L1 and / or CD40-related diseases are PD-L1-related tumors, CD40-related tumors, or PD-L1×CD40-related tumors. Preferably, the CD40-related tumors include solid tumors and hematological tumors, and the PD-L1-related tumors include solid tumors and hematological tumors. More preferably, the CD40-associated tumors include B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal cancer, malignant melanoma, pancreatic cancer and colon cancer; the PD-L1-associated tumors include squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal Large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell / histiocyte-rich large B-cell lymphoma, multiple myeloma, myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, stomach cancer, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, pharyngeal cancer, hepatobiliary cancer cancer), central nervous system cancer, esophageal cancer, malignant pleural mesothelioma, systemic light chain amyloidosis, lymphoplasmacytic lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, neuroendocrine tumors, Merkel cell carcinoma, testicular cancer and skin cancer, preferably colon cancer with high PD-L1 expression.
[0070] To solve the above technical problems, the present invention provides, on the other hand, a method for detecting PD-L1 and / or CD40 in a sample, comprising the step of contacting the sample with one or more of the antigen-binding protein targeting PD-L1 and CD40 as described in the present invention, the detection reagent as described in the present invention, and the antibody-drug conjugate as described in the present invention. The sample is, for example, a blood sample (e.g., a whole blood sample and a serum sample) and a reagent containing PD-L1 and / or CD40. Preferably, the method is for non-therapeutic / diagnostic purposes, such as detecting the concentration of PD-L1 and / or CD40 standards in scientific research, whether other reagents are contaminated by PD-L1 and / or CD40, etc.
[0071] To solve the above technical problems, the present invention provides, on the other hand, a method for diagnosing, treating and / or preventing PD-L1 and / or CD40-related diseases, comprising administering to a patient in need thereof a therapeutically effective amount of an antigen binding protein targeting PD-L1 and CD40 as described in the present invention, a chimeric antigen receptor as described in the present invention, an isolated nucleic acid as described in the present invention, a recombinant expression vector as described in the present invention, a pharmaceutical composition as described in the present invention, a detection reagent as described in the present invention, a genetically modified cell as described in the present invention, and an antibody-drug conjugate as described in the present invention, or using the kit of parts as described in the present invention to diagnose or treat a patient in need thereof. Preferably, the PD-L1 and / or CD40-related disease is a PD-L1-related tumor, a CD40-related tumor, or a PD-L1×CD40-related tumor. Preferably, the CD40-related tumor includes a solid tumor and a hematological tumor, and the PD-L1-related tumor includes a solid tumor and a hematological tumor.More preferably, the CD40-associated tumors include B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal cancer, malignant melanoma, pancreatic cancer and colon cancer; the PD-L1-associated tumors include squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal Large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell / histiocyte-rich large B-cell lymphoma, multiple myeloma, myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, stomach cancer, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, pharyngeal cancer, hepatobiliary cancer cancer), central nervous system cancer, esophageal cancer, malignant pleural mesothelioma, systemic light chain amyloidosis, lymphoplasmacytic lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, neuroendocrine tumors, Merkel cell carcinoma, testicular cancer and skin cancer, preferably colon cancer with high PD-L1 expression.
[0072] To solve the above technical problems, the present invention further provides an antigen binding protein targeting PD-L1 and CD40 as described in the present invention, a chimeric antigen receptor as described in the present invention, an isolated nucleic acid as described in the present invention, a recombinant expression vector as described in the present invention, a pharmaceutical composition as described in the present invention, a detection reagent as described in the present invention, a kit as described in the present invention, a genetically modified cell as described in the present invention, and / or an antibody-drug conjugate as described in the present invention for diagnosing, preventing, and / or treating PD-L1 and / or CD40-related diseases. Preferably, the PD-L1 and / or CD40-related diseases are PD-L1-related tumors, CD40-related tumors, or PD-L1×CD40-related tumors. Preferably, the CD40-related tumors include solid tumors and hematologic tumors, and the PD-L1-related tumors include solid tumors and hematologic tumors. More preferably, the CD40-associated tumors include B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal cancer, malignant melanoma, pancreatic cancer and colon cancer; the PD-L1-associated tumors include squamous cell carcinoma, myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal Large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell / histiocyte-rich large B-cell lymphoma, multiple myeloma, myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, stomach cancer, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, pharyngeal cancer, hepatobiliary cancer cancer), central nervous system cancer, esophageal cancer, malignant pleural mesothelioma, systemic light chain amyloidosis, lymphoplasmacytic lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, neuroendocrine tumors, Merkel cell carcinoma, testicular cancer and skin cancer, preferably colon cancer with high PD-L1 expression.
[0073] In the present invention, "having 3, 2, or 1 amino acid mutations" refers to insertions, deletions, or substitutions of amino acids in the original amino acid sequence. Exemplary explanations include CDR mutations that include 3, 2, or 1 amino acid mutations. Mutations in these CDRs can optionally involve the same or different numbers of amino acid residues. For example, a single amino acid mutation can be made in CDR1, while no amino acid mutations can be made in CDR2 or CDR3.
[0074] In the present invention, "PTM site mutation" refers to a mutation of the amino acid at the PTM site in the sequence of the variant compared to the original amino acid sequence. Depending on the difference between the antibody sequence and the PTM sequence pattern, there are different mutation design methods. One method is to replace the "hot spot" amino acid (such as N or S in the NS pattern) with an amino acid with similar physicochemical properties (such as mutating N to Q). If the PTM sequence pattern comes from a somatic high-frequency mutation and is not present in the germline gene sequence, then another method can be to replace the sequence pattern with the corresponding germline gene sequence.
[0075] In the present invention, the VH, VL, or full-length antibody may include mutations based on the defined sequences. The mutation is a deletion, substitution, or addition of one or more amino acid residues to the defined amino acid sequence, and the mutated amino acid sequence has at least 80% sequence identity with the defined amino acid sequence and maintains or improves the binding activity of the antigen-binding protein containing the mutated amino acid sequence; the at least 80% sequence identity is preferably at least 85% sequence identity, 90% sequence identity, more preferably at least 95% sequence identity, and most preferably at least 99% sequence identity.
[0076] In the present invention, “including”, “comprising” and “for” have the same meaning in certain specific embodiments.
[0077] On the basis of conforming to the common sense in this field, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0078] The reagents and raw materials used in the present invention are commercially available.
[0079] The positive progress effect of the present invention is:
[0080] The antigen binding protein targeting CD40 described in the present invention has high affinity for CD40 and strong agonist activity on signaling pathways, especially enhanced agonist activity after cross-linking, which gives the antigen binding protein targeting CD40 described in the present invention a larger therapeutic window and provides a good foundation for significantly improving patient response rates under safe and tolerable dose conditions in clinical trials. The antigen binding protein targeting PD-L1 described in the present invention has high affinity for PD-L1 and can effectively inhibit the biological activity of PD-L1. On this basis, the antigen binding protein targeting PD-L1 and CD40 described in the present invention has excellent anti-tumor efficacy, good safety, and outstanding drugability. The antigen binding protein targeting PD-L1 and CD40 described in the present invention blocks the PD-1 / PD-L1 inhibitory signaling pathway and acts on the activating CD40 receptor, thereby simultaneously activating antigen-presenting cells and lymphocytes, enhancing the presentation of tumor antigens by antigen-presenting cells to lymphocytes, and promoting the response of lymphocytes, thereby achieving a significant synergistic anti-tumor effect. At the same time, the activation of immune cells by the antigen binding protein targeting PD-L1 and CD40 only occurs in the tumor microenvironment, significantly eliminating the problems of systemic drug toxicity and side effects, allowing the antigen binding protein to exert its excellent anti-tumor efficacy under very safe conditions. Currently, no new antibody drugs with this target combination are available on the market domestically or internationally, and this invention is expected to bring new opportunities for the treatment of various tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] FIG1A to FIG1D respectively show the levels of binding of some CD40 antibodies of the present invention to Raji cells that highly express human CD40.
[0082] Figure 2A shows the activation effect of PR003379 on HEK293-hCD40-NFκB fluorescent reporter gene cells with or without cell-mediated cross-linking expressing human CD32B. Figure 2B shows the activation effect of control Selicrelumab on HEK293-hCD40-NFκB fluorescent reporter gene cells with or without cell-mediated cross-linking expressing CD32B. Figure 2C shows the activation effect of other CD40 antibodies on HEK293-hCD40-NFκB fluorescent reporter gene cells with CD32B cell-mediated cross-linking. Figure 2D shows the activation effect of other CD40 antibodies on HEK293-hCD40-NFκB fluorescent reporter gene cells without cell-mediated cross-linking expressing human CD32B.
[0083] FIG3A and FIG3B respectively show the levels of binding of some PD-L1 antibodies of the present invention to CHO-K1 cells (CHO-K1 / hPD-L1) that highly express human PD-L1.
[0084] FIG4A and FIG4B respectively show the inhibitory effects of some PD-L1 antibodies of the present invention on the PD-1 signaling pathway in reporter gene cell experiments.
[0085] FIG5 shows a schematic diagram of the molecular structure of the PD-L1×CD40 bispecific binding protein.
[0086] FIG6A and FIG6B respectively show the levels of binding of some PD-L1×CD40 bispecific binding proteins of the present invention to human PD-L1 cells CHO-K1 / hPD-L1.
[0087] FIG7A and FIG7B respectively show the levels of binding of some PD-L1×CD40 bispecific binding proteins of the present invention to cynomolgus monkey PD-L1 cells CHO-K1 / cyPD-L.
[0088] FIG8A and FIG8B respectively show the levels of binding of some PD-L1×CD40 bispecific binding proteins of the present invention to human CD40 cells CHO-K1 / hCD40.
[0089] FIG9A and FIG9B respectively show the levels of binding of some PD-L1×CD40 bispecific binding proteins of the present invention to cynomolgus monkey CD40 cells CHO-K1 / cyCD40.
[0090] FIG10A and FIG10B respectively show that some PD-L1×CD40 bispecific binding proteins of the present invention do not bind to CHO-K1 cells.
[0091] FIG11A and FIG11B respectively show the levels of binding of some PD-L1×CD40 bispecific binding proteins of the present invention to NCI-H226 cells that highly express human PD-L1.
[0092] FIG12A and FIG12B respectively show the levels of binding of some PD-L1×CD40 bispecific binding proteins of the present invention to Raji cells that highly express human CD40.
[0093] FIG13A and FIG13B respectively show the binding levels of some PD-L1×CD40 bispecific binding proteins of the present invention to MDA-MB-231 cells expressing human PD-L1 and human CD40.
[0094] Figures 14A and 14B show the first batch of experiments on the inhibitory effect of PD-L1×CD40 bispecific binding protein on the PD-1 signaling pathway in reporter gene cell experiments, and Figures 14C and 14D show the second batch of experiments on the inhibitory effect of PD-L1×CD40 bispecific binding protein on the PD-1 signaling pathway in reporter gene cell experiments.
[0095] Figures 15A-15C show the first batch of experiments on the activation effect of PD-L1×CD40 bispecific binding protein on the CD40 signaling pathway in reporter gene cell experiments, Figures 15D and 15E show the second batch of experiments on the activation effect of PD-L1×CD40 bispecific binding protein on the CD40 signaling pathway in reporter gene cell experiments, and Figures 15F-15K show the third batch of experiments on the activation effect of PD-L1×CD40 bispecific binding protein on the CD40 signaling pathway in reporter gene cell experiments.
[0096] FIG16A and FIG16B respectively show the levels of IL12p40 secretion promoted by activation of human DC cells (donor #1) by some PD-L1×CD40 bispecific binding proteins of the present invention.
[0097] FIG17A and FIG17B respectively show the levels of IL12p40 secretion promoted by activation of human DC cells (donor #2) by some PD-L1×CD40 bispecific binding proteins of the present invention.
[0098] FIG18A and FIG18B respectively show the levels of IL12p40 secretion promoted by activation of human DC cells (donor #3) by some PD-L1×CD40 bispecific binding proteins of the present invention.
[0099] Figures 19A-19B show the levels of IL12p40 secretion promoted by iDC cells by activating human DC cells (donor #4) with the PD-L1×CD40 bispecific binding protein. Figures 19C-19D show the levels of IL12p40 secretion promoted by mDC cells by activating human DC cells (donor #4) with the PD-L1×CD40 bispecific binding protein.
[0100] FIG20 shows the level of promotion of human B cell (donor #1) proliferation by PD-L1×CD40 bispecific binding protein.
[0101] FIG21 shows the level of promotion of human B cell (donor #2) proliferation by PD-L1×CD40 bispecific binding protein.
[0102] FIG22A and FIG22B respectively show the levels of human B cell (donor #3) proliferation promoted by some PD-L1×CD40 bispecific binding proteins of the present invention.
[0103] FIG23A and FIG23B respectively show the levels of human B cell (donor #4) proliferation promoted by some PD-L1×CD40 bispecific binding proteins of the present invention.
[0104] FIG24A and FIG24B respectively show the levels of human B cell (donor #5) proliferation promoted by some PD-L1×CD40 bispecific binding proteins of the present invention.
[0105] Figure 25A shows the changes in tumor volume during the in vivo anti-tumor efficacy of the PD-L1×CD40 bispecific binding protein in mice (Mouse Efficacy Experiment #1), and Figure 25B shows the changes in mouse weight during the in vivo anti-tumor efficacy of the PD-L1×CD40 bispecific binding protein in mice (Mouse Efficacy Experiment #1).
[0106] Figure 26A shows the changes in tumor volume during the in vivo anti-tumor efficacy of the PD-L1×CD40 bispecific binding protein in mice (Mouse Efficacy Experiment #2), and Figure 26B shows the changes in mouse weight during the in vivo anti-tumor efficacy of the PD-L1×CD40 bispecific binding protein in mice (Mouse Efficacy Experiment #2).
[0107] Figure 27A shows the changes in tumor volume during the in vivo anti-tumor efficacy of the PD-L1×CD40 bispecific binding protein in mice (Mouse Efficacy Experiment #3), and Figure 27B shows the changes in mouse weight during the in vivo anti-tumor efficacy of the PD-L1×CD40 bispecific binding protein in mice (Mouse Efficacy Experiment #3).
[0108] Figure 28 shows the effects of PD-L1×CD40 bispecific binding protein and Selicrelumab on mouse liver function indicators ALT and AST in mouse efficacy experiment #3.
[0109] FIG29 shows the results of staining analysis of mouse liver tissue sections in mouse efficacy experiment #3.
[0110] Figure 30A shows the changes in tumor volume during the anti-tumor efficacy of PD-L1×CD40 bispecific binding protein and Selicrelumab in mice (Mouse Efficacy Experiment #4), and Figure 30B shows the changes in mouse weight during the anti-tumor efficacy of PD-L1×CD40 bispecific binding protein and Selicrelumab in mice (Mouse Efficacy Experiment #4).
[0111] Figure 31 shows the effects of PD-L1×CD40 bispecific binding protein and Selicrelumab on mouse liver function indicators ALT and AST in mouse efficacy experiment #4.
[0112] FIG32 shows the levels of cytokines (IL-6, IFN-γ) in peripheral blood of mice in mouse efficacy experiment #4.
[0113] FIG33 shows the levels of cytokines (TNF-α, IL12p40) in peripheral blood of mice in mouse efficacy experiment #4.
[0114] FIG34 shows the results of staining analysis of mouse liver tissue sections in mouse efficacy experiment #4.
[0115] Figure 35A shows the pharmacokinetics of PR007619PD-L1×CD40 bispecific binding protein in mice, Figure 35B shows the pharmacokinetics of PR007556PD-L1×CD40 bispecific binding protein in mice, Figure 35C shows the pharmacokinetics of PR007281PD-L1×CD40 bispecific binding protein in mice, and Figure 35D shows the pharmacokinetics of PR007276PD-L1×CD40 bispecific binding protein in mice; in the figures, Total refers to Fc-end detection, and Free refers to PD-L1-end detection. DETAILED DESCRIPTION
[0116] The following describes the implementation of the present invention through specific embodiments. People familiar with this technology can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.
[0117] In this application, the term "binding protein" or "antigen binding protein" generally refers to a protein comprising a portion that binds to an antigen, and optionally a scaffold or backbone portion that allows the portion that binds to the antigen to adopt a conformation that promotes binding of the antigen binding protein to the antigen. It may typically comprise an antibody light chain variable region (VL), an antibody heavy chain variable region (VH), or both. The VH and VL regions can be further divided into hypervariable regions called complementarity determining regions (CDRs), which are interspersed in more conserved regions called framework regions (FRs). Each VH and VL can be composed of three CDRs and four FR regions, which can be arranged in the following order from amino terminus to carboxyl terminus: FR-1, CDR1, FR-2, CDR2, FR-3, CDR3, and FR-4. The variable regions of the heavy and light chains contain binding domains that interact with the antigen. The three CDRs of VH are represented as HCDR1, HCDR2, and HCDR3, respectively, and may also be represented as VH CDR1, VH CDR2, and VH CDR3; the three CDRs of VL are represented as LCDR1, LCDR2, and LCDR3, respectively, and may also be represented as VL CDR1, VL CDR2, and VL CDR3. Examples of antigen-binding proteins include, but are not limited to, antibodies, antigen-binding fragments (Fab, Fab', F(ab)2, Fv fragment, F(ab')2, scFv, di-scFv, and / or dAb), immunoconjugates, multispecific antibodies (e.g., bispecific antibodies), antibody fragments, antibody derivatives, antibody analogs, or fusion proteins, so long as they exhibit the desired antigen-binding activity.
[0118] In the present application, the amino acid sequence of the CDR is shown in accordance with the Chothia definition rule. However, it is well known to those skilled in the art that the CDR of an antibody can be defined in this area by a variety of methods, such as the Kabat definition rule based on sequence variability (see, Kabat et al., Protein Sequences in Immunology, 5th edition, National Institutes of Health, Bethesda, Maryland (1991)) and the Chothia definition rule based on the structural loop region position (see J Mol Biol 273:927-48,1997). In the technical scheme of the present invention, the Combined definition rule comprising the Kabat definition and the Chothia definition can also be used to determine the amino acid residues in the variable domain sequence. Wherein the Combined definition rule is to combine the scope of the Kabat definition and the Chothia definition, and based on this, a larger scope is taken, see Table 2 below for details. It will be understood by those skilled in the art that, unless otherwise specified, the term "CDR" and "complementary determining region" of a given antibody or its district (such as variable region) should be understood to encompass the complementary determining region defined as defined in any of the above-mentioned known schemes described by the present invention. Although the scope of protection claimed in the present invention is based on the sequence shown in the Chothia definition rules, the amino acid sequences corresponding to other CDR definition rules should also fall within the scope of protection of the present invention.
[0119] Table 2 Antibody CDR definition method in this application
[0120] Among them, Laa-Lbb can refer to the amino acid sequence starting from the N-terminus of the antibody light chain, from position aa (Chothia numbering rules) to position bb (Chothia numbering rules); Haa-Hbb can refer to the amino acid sequence starting from the N-terminus of the antibody heavy chain, from position aa (Chothia numbering rules) to position bb (Chothia numbering rules). For example, L24-L34 can refer to the amino acid sequence starting from the N-terminus of the antibody light chain, from position 24 to position 34 according to the Chothia numbering rules; H26-H32 can refer to the amino acid sequence starting from the N-terminus of the antibody heavy chain, from position 26 to position 32 according to the Chothia numbering rules. It should be known to those skilled in the art that when using Chothia to encode CDRs, some positions may have insertion sites (see http: / / bioinf.org.uk / abs / ).
[0121] In this application, the term "monoclonal antibody" generally refers to the antibody obtained from a group of substantially homogeneous antibodies, i.e., the individual antibodies in the cluster are identical, except for a small amount of natural mutations that may exist. Monoclonal antibodies are generally highly specific for a single antigenic site. And, different from conventional polyclonal antibody preparations (generally having different antibodies for different determinants), each monoclonal antibody is for a single determinant on the antigen. Except for their specificity, the advantage of monoclonal antibodies is that they can be synthesized by hybridoma culture, and are not polluted by other immunoglobulins. The modifier "monoclonal" represents the feature of the antibody obtained from a substantially homogeneous antibody colony, and is not interpreted as needing to produce antibody by any ad hoc method. For example, the monoclonal antibody used according to the present invention can be prepared in hybridoma cell, or can be prepared by recombinant DNA method.
[0122] In this application, the term "fully human antibody" generally refers to antibodies expressed by animals that have transferred all human antibody-encoding genes into genetically engineered antibody gene-deficient animals. All parts of the antibody (including the variable and constant regions of the antibody) are encoded by genes of human origin. Fully human antibodies can greatly reduce the immune side effects caused by heterologous antibodies to the human body. Methods for obtaining fully human antibodies in this field include phage display technology, transgenic mouse technology, etc.
[0123] In this application, the term "specific binding" generally refers to the binding of an antibody to an epitope through its antigen binding domain, and this binding requires some complementarity between the antigen binding domain and the epitope. According to this definition, an antibody is said to "specifically bind" to an antigen when it binds to an epitope more easily through its antigen binding domain than it would to a random, unrelated epitope. An "epitope" refers to a specific group of atoms (e.g., a sugar side chain, a phosphoryl group, a sulfonyl group) or an amino acid on an antigen that binds to an antigen-binding protein (such as an antibody).
[0124] In this application, the term "Fab" generally refers to the antigen-binding portion of a conventional antibody (e.g., IgG), comprising the antibody's heavy chain variable region VH, light chain variable region VL, heavy chain constant region domain CHI, and light chain constant region CL. In conventional antibodies, the C-terminus of VH is linked to the N-terminus of CHI to form the heavy chain Fd fragment, the C-terminus of VL is linked to the N-terminus of CL to form the light chain, and the C-terminus of CHI is further linked to the hinge region and other constant region domains of the heavy chain to form the heavy chain. In some embodiments, "Fab" also refers to variant structures of Fab. For example, in certain embodiments, the C-terminus of VH is linked to the N-terminus of CL to form one polypeptide chain, and the C-terminus of VL is linked to the N-terminus of CHI to form another polypeptide chain, forming a Fab (cross VH / VL) structure. In certain embodiments, the CHI of Fab is not linked to the hinge region, but the C-terminus of CL is linked to the hinge region of the heavy chain, forming a Fab (cross Fd / LC) structure.
[0125] In this application, the term "VH" generally refers to the heavy chain variable region VH domain of an antibody, that is, it can be the heavy chain variable region VH of a conventional antibody (H2L2 structure) of humans or other animals, or the heavy chain variable region VHH of a heavy chain antibody (HCAb structure) of animals such as camelids, or the heavy chain variable region VH of a fully human heavy chain antibody (HCAb structure) produced using Harbour HCAb transgenic mice.
[0126] In this application, the term "antigen-binding fragment" generally refers to any functional region of a protein that can specifically bind to an antigen, and can be "Fab", "VH", or other antigen-binding forms (such as lipocalins, neural cell adhesion molecules (NCAM), fibronectin, ankyrin repeat proteins (DARPins) and other derived protein structures).
[0127] In this application, the term "tumor antigen" can refer to either a tumor-specific antigen (TSA) or a tumor-associated antigen (TAA). Tumor-specific antigens are antigens that are specific to tumor cells and not present on normal cells or tissues. Tumor-associated antigens are not specific to tumor cells and are also present on normal cells or tissues, but are highly expressed when tumor cells proliferate.
[0128] In this application, the term "target cells" refers to cells that need to be eliminated, mainly tumor cells, but also immunosuppressive cells, etc.
[0129] In this application, the term "immune effector cells" generally refers to immune cells that participate in the clearance of foreign antigens and perform effector functions in immune responses, such as plasma cells, cytotoxic T cells, NK cells, etc.
[0130] In this application, the terms "costimulatory molecules," "costimulatory molecule antigens," or "stimulatory antigens" refer to cell surface molecules and their ligands that provide costimulatory signals for the full activation of immune cells, such as T or B cells, and play a positive regulatory role in immune cell activation. Examples include CD28, 4-1BB, ICOS, OX40, CD40, and the like.
[0131] In this application, the term "co-inhibitory molecule" or "co-inhibitory molecule antigen" refers to a class of cell surface molecules and their ligands that negatively regulate the function of immune cells, such as CTLA-4, PD-L1, PD-1, etc.
[0132] In this application, the term "PD-L1" generally refers to programmed death ligand 1 protein, its functional variants and / or its functional fragments. PD-L1 is also known as cluster of differentiation 274 (CD274) or B7 homolog 1 (B7-H1) and is a protein encoded by the CD274 gene (in humans). PD-L1 sequences are known in the art. For example, the amino acid sequence of an exemplary full-length human PD-L1 protein can be found under NCBI accession number NP_054862 or UniProt accession number Q9NZQ7; an exemplary full-length cynomolgus monkey PD-L1 protein sequence can be found under NCBI accession number XP_005581836 or UniProt accession number G7PSE7.
[0133] In this application, the term "CD40" generally refers to the tumor necrosis factor receptor superfamily member 5 protein, its functional variants, and / or functional fragments thereof, also known as TNFRSF5. CD40 sequences are known in the art. For example, an exemplary amino acid sequence of human CD40 protein can be found under UniProt Accession No. P25942; an exemplary cynomolgus monkey CD40 protein sequence can be found under UniProt Accession No. G7PG38; and an exemplary mouse CD40 protein sequence can be found under UniProt Accession No. P27512. CD40L is the natural trimeric ligand molecule for CD40.
[0134] Example
[0135] The present invention is further illustrated by the following examples, which are not intended to limit the invention to these examples. The examples do not include detailed descriptions of conventional methods, such as those used to construct vectors and plasmids, insert protein-encoding genes into such vectors and plasmids, or introduce plasmids into host cells. Such methods are well known to those skilled in the art and are described in numerous publications. Experimental procedures in the following examples, where specific conditions are not specified, were performed according to conventional methods and conditions or as selected from commercially available product specifications.
[0136] Example 1 Expression, purification and physicochemical characterization of recombinant antibodies
[0137] Example 1.1 Expression and purification of antibodies
[0138] This example describes a general method for producing antibodies using mammalian host cells (e.g., human embryonic kidney (HEK293) cells or Chinese hamster ovary (CHO) cells and their derivatives), transient transfection expression, and affinity capture isolation. This method is applicable to target antibodies containing an Fc region; the target antibody can be composed of one or more protein polypeptide chains and can be derived from one or more expression plasmids.
[0139] The amino acid sequence of the antibody polypeptide chain is converted into a nucleotide sequence through codon optimization methods; the encoding nucleotide sequence is synthesized and cloned into an expression vector compatible with the host cell. The plasmids encoding the antibody polypeptide chain are simultaneously transfected into mammalian host cells at a specific ratio, and conventional recombinant protein expression and purification techniques are used to obtain recombinant antibodies with correct folding and polypeptide chain assembly. Specifically, FreeStyle TM 293-F cells (Thermo, #R79007) were cultured in FreeStyle TM Before transient transfection, adjust the cell density to 6-8×10 5 cells / mL, and cultured in a shaker at 37°C with 8% CO2 for 24 hours. The cell concentration was 1.2×10 6Cells / mL. Prepare 30mL of cultured cells. The plasmid encoding the antibody polypeptide chain (pTT5, NRC) was mixed in a certain proportion, and a total of 30μg of plasmid (the ratio of plasmid to cells was 1μg:1mL) was dissolved in 1.5mL of Opti-MEM reduced serum medium (Thermo, #31985088), and sterilized by filtration with a 0.22μm filter membrane. Then 1.5mL of Opti-MEM was dissolved in 120μL of 1mg / mL PEI (Polysciences, #23966-2) and allowed to stand for 5 minutes. Slowly add PEI to the plasmid, incubate at room temperature for 10 minutes, and slowly drip the plasmid PEI mixed solution while shaking the culture flask. Culture in a shaker at 37℃ with 8% CO2 for 5 days. Observe cell viability after 5 days. Collect the culture, centrifuge at 3300g for 10 minutes, and take the supernatant; then centrifuge the supernatant at high speed to remove impurities. Use PBS pH7.4 buffer to equilibrate the cells containing MabSelect. TM (GE Healthcare, #71-5020-91) gravity column (Bio-Rad, #7311550), 2-5 column volumes of washing. The supernatant sample was passed through the column; the column was washed with 5-10 column volumes of PBS buffer, and the target protein was eluted with 0.1M glycine at pH 3.5, and then adjusted to neutral with Tris-HCl at pH 8.0. Finally, the solution was concentrated with an ultrafiltration tube (Millipore, #UFC901024) and replaced with PBS buffer or a buffer containing other components to obtain a purified recombinant antibody solution. Finally, the purified recombinant antibody solution was purified using NanoDrop (Thermo, NanoDrop TM One) Determine the concentration, aliquot, and store for future use.
[0140] Example 1.2 Analysis of protein purity and aggregates using SEC-HPLC
[0141] This embodiment uses analytical size exclusion chromatography (SEC) to analyze the purity and polymer form of protein samples. The analytical chromatographic column TSKgel G3000SWxl (Tosoh Bioscience, #08541, 5μm, 7.8mm×30cm) is connected to a high pressure liquid chromatograph HPLC (Agilent Technologies, Agilent 1260Infinity II) and balanced at room temperature for at least 1 hour with PBS buffer (pH 7.4). An appropriate amount of protein sample (at least 10μg) is filtered with a 0.22μm filter membrane and injected into the system, and the HPLC program is set: the sample is passed through the chromatographic column at a flow rate of 1.0mL / min with PBS buffer (pH 7.4) for a maximum of 25 minutes. The HPLC will generate an analysis report reporting the retention time of different molecular size components in the sample.
[0142] Example 1.3 Determination of thermal stability of protein molecules using DSF
[0143] Differential Scanning Fluorimetry (DSF) is a commonly used high-throughput method for determining protein thermal stability. It uses a real-time fluorescence quantitative PCR instrument to monitor the changes in the fluorescence intensity of the dye bound to the unfolded protein molecule to reflect the process of protein denaturation, thereby reflecting the thermal stability of the protein molecule. This example uses the DSF method to determine the thermal denaturation temperature (Tm) of the protein molecule. 10 μg of protein was added to a 96-well PCR plate (Thermo, #AB-0700 / W), followed by the addition of 2 μL of 100× diluted dye SYPROTM (Invitrogen, #2008138), and then buffer was added to make the final volume 40 μL per well. The PCR plate was sealed and placed in a real-time fluorescence quantitative PCR instrument (Bio-Rad CFX96PCR System). It was first incubated at 25°C for 5 minutes, then gradually increased from 25°C to 95°C in a gradient of 0.2°C / 0.2 minutes, and the temperature was lowered to 25°C at the end of the test. The FRET scanning mode was used and Bio-Rad CFX Maestro software was used for data analysis and calculation of the Tm of the samples.
[0144] Example 2 Preparation of CD40 Antibody
[0145] Antibodies that specifically bind to CD40 can be obtained by immunizing experimental animals with the CD40 antigen. These experimental animals can include mice, rats, rabbits, sheep, camels, and others. Typically, the resulting antibodies are non-human. After obtaining non-human antibodies, these molecules need to be humanized using antibody engineering techniques to reduce immunogenicity and improve drugability. However, the humanization process is technically complex, and humanized molecules often have reduced affinity for the antigen. On the other hand, advances in transgenic technology have enabled the creation of genetically engineered mice that carry a human immunoglobulin repertoire and lack the endogenous murine immune repertoire. The antibodies produced by these transgenic mice possess fully human sequences, eliminating the need for further humanization and significantly improving the efficiency of therapeutic antibody development. Harbour H2L2 mice (Harbour Antibodies BV) are transgenic mice that carry a human immunoglobulin repertoire and produce antibodies with a complete human variable domain and rat constant domains.
[0146] Immunization of mice
[0147] Harbour H2L2 mice were immunized multiple times with a soluble recombinant human CD40 extracellular domain fusion protein (Acrobiosystems, #CD0-H5253). The antigen protein was mixed with an immune adjuvant to form an immunogen, which was then injected subcutaneously into the inguinal cavity or intraperitoneally. In each round of immunization, each mouse received a total injection dose of 100 μL. In the first round of immunization, each mouse received an immunogen prepared by mixing 50 μg of the antigen protein with complete Freund's adjuvant (Sigma, #F5881) at a 1:1 volume ratio. In each subsequent booster round, each mouse received an immunogen prepared by mixing 25 μg of the antigen protein with Sigma Adjuvant System adjuvant (Sigma, #S6322). Each booster round was separated by at least two weeks, and typically did not exceed five rounds. Immunizations were performed on days 0, 14, 28, 42, 56, and 70, and serum antibody titers were measured on days 49 and 77. Three days before cell fusion, a final booster immunization was performed with 25 μg of antigen protein per mouse.
[0148] Hybridoma screening
[0149] After the CD40-specific antibody titer in mouse serum reached a certain level, the mouse spleen cells were removed and fused with a myeloma cell line to generate hybridoma cells. After multiple rounds of screening and cloning, hybridomas expressing CD40 monoclonal antibody molecules were isolated. The isolated hybridomas expressed antibody molecules with complete human variable domains and rat constant domains for both heavy and light chains. These monoclonal antibodies were further characterized, and several hybridoma clones were selected for sequencing based on parameters such as their binding ability to human CD40, cynomolgus monkey CD40, and their ability to activate CD40 downstream signaling pathways. Selicrelumab (also designated PR001028 in this application) was used as a positive control antibody during the screening process. The nucleotide sequence encoding the variable domain of the antibody molecule and the corresponding amino acid sequence were obtained using conventional hybridoma sequencing methods. In this example, the variable domain sequence of the CD40 monoclonal antibody molecule obtained from immunized Harbour H2L2 mice was a human antibody sequence. The CDR sequences of the antibody variable domain can be analyzed using Kabat or Chothia or other CDR definition rules (Table-1).
[0150] Recombinant IgG antibodies and sequence analysis and optimization
[0151] After obtaining the light and heavy chain variable domain sequences encoding the antibody molecule, conventional recombinant DNA technology can be used to fuse the light and heavy chain variable domain sequences with the corresponding human antibody light and heavy chain constant domain sequences to obtain recombinant antibody molecules using the method described in 0. In this embodiment, the antibody heavy chain variable domain sequence (VH) is synthesized by gene synthesis and cloned into a mammalian cell expression plasmid vector encoding a human IgG1 or IgG2 antibody heavy chain constant domain sequence to encode the full-length heavy chain of the IgG antibody. The antibody light chain variable domain sequence (VL) is synthesized by gene synthesis and cloned into a mammalian cell expression plasmid vector encoding a human antibody Igκ light chain constant domain sequence to encode the full-length light chain of the antibody. In this embodiment, a fully human anti-CD40 recombinant IgG antibody is obtained.
[0152] The sequence of an antibody's heavy chain variable domain is derived from rearrangement and somatic hypermutation of the germline V, D, and J gene segments of the heavy chain gene group on chromosomes. The sequence of the light chain variable domain is derived from rearrangement and somatic hypermutation of the germline V and J gene segments of the light chain gene group. Rearrangement and somatic hypermutation are major factors contributing to antibody diversity. Antibodies derived from the same germline V gene segment may have different sequences, but overall they are highly similar. Using algorithms such as IMGT / DomainGapAlign (http: / / imgt.org / 3Dstructure-DB / cgi / DomainGapAlign.cgi) or NCBI / IgBLAST (https: / / www.ncbi.nlm.nih.gov / igblast / ), it is possible to infer the germline gene segments from which rearrangements occurred based on the variable domain sequence of an antibody.
[0153] After protein or polypeptide amino acid chains are translated and synthesized in cells, chemical modifications sometimes occur, known as post-translational modifications (PTMs). For antibodies, some PTM sites are highly conserved. For example, the conserved amino acid asparagine (Asn) at position 297 (EU numbering) in the constant domain of human IgG1 antibodies is commonly glycosylated to form sugar chains, which are crucial for antibody structure and associated effector functions. However, if PTMs exist in the variable domains of antibodies, especially in the antigen-binding regions (such as CDRs), they may significantly affect antigen binding and may also alter the antibody's physicochemical properties. For example, glycosylation, deamidation, isomerization, and oxidation can increase the instability or heterogeneity of antibody molecules, thereby increasing the difficulty and risk of antibody development. Therefore, avoiding potential PTMs is crucial for the development of therapeutic antibodies. With accumulated experience, it has been found that some PTMs are highly correlated with the composition of the amino acid sequence, especially the "pattern" of adjacent amino acids, making it possible to predict potential PTMs from the primary amino acid sequence of a protein. For example, the sequence pattern NxS / T (asparagine at the first position, any amino acid other than proline at the second position, and serine or threonine at the third position) predicts an N-linked glycosylation site. The amino acid sequence pattern that causes a PTM may originate from the germline gene sequence, such as the naturally occurring glycosylation pattern NST in the FR3 region of the human germline gene fragment IGHV3-33. It may also arise from somatic high-frequency mutations. Specifically, NGS or NLT may represent a glycosylation site, NS may represent a deamidation site, and DG may cause isomerization of aspartate. Amino acid mutations can disrupt the amino acid sequence pattern of a PTM, thereby reducing or eliminating the formation of a specific PTM. Different mutation design approaches are used depending on the antibody sequence and the PTM sequence pattern. One approach involves replacing "hotspot" amino acids (such as N or S in the NS pattern) with amino acids with similar physicochemical properties (e.g., mutating N to Q). Another approach involves randomly mutating the PTM sequence pattern using a mutation library. In practice, multiple mutation design approaches may be used for the same PTM sequence pattern.
[0154] Table 3 lists the anti-CD40 hybridoma clones and recombinant antibody molecules (PR003379) obtained in this example, as well as the analyzed VH and VL germline gene V gene segments and potential PTM sites.
[0155] Table 4 lists novel antibody molecules obtained by amino acid mutation of the CD40 antibody PR003379. All designed mutant molecules were purified as recombinant antibodies according to the method described in [0] and further validated in subsequent functional experiments. The antibodies in Table 5 were obtained by linking the heavy chain variable region (VH) of PR003379 to the heavy chain constant domain sequence of an IgG1 subtype antibody containing the L234A, L235A, and G237A mutations and cloning it into a mammalian cell expression plasmid to encode the full-length IgG1 (L234A, L235A, G237A) heavy chain. The antibody light chain variable domain sequence (VL) containing the PTM mutation site was synthesized and cloned into a mammalian cell expression plasmid vector encoding the human Igκ light chain constant domain sequence to encode the full-length light chain of the antibody. The two plasmids were co-transfected into mammalian cells, and after expression, production and purification, a fully human anti-CD40 recombinant IgG1 (L234A, L235A, G237A) antibody was obtained.
[0156] Table 5 lists the sequences of the CD40 antibodies in the present application and the amino acid sequences of the CDRs defined according to the Chothia definition rules. These CD40 antibodies include a positive control antibody, the CD40 antibody PR003379 of the present invention, and mutant molecules thereof.
[0157] Table 3: Germline gene analysis and PTM site analysis of CD40 antibodies
[0158] Table 4: Mutation site design of CD40 antibody PR003379
[0159] Table 5: Sequence numbering table of CD40 antibody sequences and CDR sequences (Chothia) in the present application
[0160] Example 3 CD40 antigen binding protein binds to cells expressing CD40
[0161] In this example, flow cytometry (FACS) was used to investigate the binding activity of CD40-targeting antibodies or antigen-binding proteins to cells expressing CD40. For example, the CHO-K1 cell line CHO-K1 / hCD40 (Shanghai Ruizhi Chemical) that overexpresses human CD40, the CHO-K1 cell line CHO-K1 / cyCD40 (Shanghai Ruizhi Chemical) that overexpresses cynomolgus monkey CD40, and the lymphoma Raji cell line (ATCC, #CCL-86) that overexpresses human CD40.
[0162] Specifically, cells expressing CD40 were digested and resuspended in complete culture medium (F-12K for CHO-K1 cells and RPMI-1640 for Raji cells); the cell density was adjusted to 1×10 6 Cells / mL. 100 μL cells / well were seeded in a 96-well V-bottom plate (Corning, #3894), followed by adding 100 μL / well of the antibody to be tested at 2 times the final concentration and mixing evenly. The highest final concentration of the antibody was 300 nM, with a total of 8 concentrations, 5-fold concentration gradient dilution, and hIgG (Crownbio, #C0002) as a negative control, and the positive control molecule was Selicrelumab. The concentration settings were the same as the subsequent tested double antibodies. The cells were placed at 4 ° C and incubated in the dark for 1 hour. Afterwards, 100 μL / well pre-cooled PBS was added to rinse the cells twice, centrifuged at 500g, 4 ° C for 5 minutes, and the supernatant was discarded. Then 100 μL / well fluorescent secondary antibody (goat anti-human IgG (H+L) secondary antibody, Alexa 488 conjugate, Invitrogen, #A11013, 1:1000 dilution) and incubate at 4°C in the dark for 30 minutes. Wash cells twice with 200 μL / well of pre-cold PBS, centrifuge at 500g for 5 minutes at 4°C, and discard the supernatant. Finally, resuspend cells in 200 μL / well of pre-cold PBS. Fluorescence and luminescence signals were read using a BD FACS CANTO II flow cytometer or an ACEA NovoCyte flow cytometer, and data were processed and analyzed using FlowJo v10 software (FlowJo, LLC).
[0163] GraphPad Prism 8 software was used for data processing and graphical analysis. The binding curve of the antibody to the target cell and the EC were obtained by four-parameter nonlinear fitting. 50 Value and other parameters.
[0164] Figures 1A-1D and Table 6 show the binding activity of CD40 antibody PR003379 and its variant molecules to Raji cells. The results show that PR003379 and its variant molecules can strongly bind to Raji cells; moreover, the binding activity of PR003379 is stronger than that of Selicrelumab.
[0165] Table 6: CD40 antibody binding to Raji cells (corresponding to Figure 1A-Figure 1D)
[0166] Example 4 Activity of CD40 Antigen Binding Protein in Fluorescent Reporter Gene Assay
[0167] This example utilizes HEK293-hCD40-NFκB fluorescent reporter cell activation assays (BPS Bioscience, #60626) to investigate the CD40 activation effects of CD40-targeting antibodies or antigen-binding proteins with and without crosslinking. Fc-mediated crosslinking of the test molecules was performed using cells that overexpress human CD32B to investigate whether crosslinking further enhances CD40 activation.
[0168] CHO-K1 cells expressing human CD32B (CHO-K1 / hCD32B (GenScript, #M00600) and CHO-K1 cells were cultured at 1×10 4 / well, 100 μL / well was plated into a 96-well plate (PerkinElmer, #6005181), and incubated overnight at 37°C in a 5% CO2 environment. The supernatant was removed, and HEK293-hCD40-NFκB reporter gene cells (BPS bioscience, #60626) expressing human CD40 and NFκB-luciferase reporter genes were collected and plated at 5×10 4 / well, add 50 μL / well to a 96-well plate. Add 50 μL / well of the test antibody dilution solution, starting at 100 nM, and dilute 5-fold, for a total of 8 concentrations. Incubate at 37°C in a 5% CO2 environment for 6 hours. Add ONE-Glo TM Luciferase reagent (Promega, #E6110) was incubated at room temperature for 5 minutes, and the luminescence value was detected by microplate reader. GraphPad Prism 8 software was used for data processing and graphical analysis. The curve of relative fluorescence signal unit (RLU) and EC value of antibody concentration dependence were obtained by four-parameter nonlinear fitting. 50 Samples incubated with CD40 antibody and CHO-K1 / hCD32B cells are called "crosslinked"; samples incubated with CD40 antibody and CHO-K1 cells are not crosslinked.
[0169] As shown in Figures 2A-2B and Table 7, PR003379 has a more obvious "cross-linking enhancement" effect than the control antibody Selicrelumab. That is, under the condition of CD32B-mediated antibody cross-linking, PR003379 can significantly amplify the signal of the fluorescent reporter gene, indicating that it significantly enhances the activation of downstream signaling molecules of the CD40 molecule.
[0170] Figures 2C-2D and Table 8 show the fluorescence intensity enhancement folds of PR003379 variants on reporter gene cells activated with or without cross-linking mediated by cells expressing human CD32B. The results show that PR003379 variants can significantly enhance the activation of CD40 molecules under cross-linking conditions, as shown by their EC 50 The value of cross-linked EC decreased significantly compared with the non-cross-linked EC 50 / Cross-linked EC 50 )”>1).
[0171] Table 7: Activity of CD40 antibodies in activating HEK293-hCD40-NFκB reporter cells
[0172] Table 8: PR003379 variants activate reporter gene cell activity under cross-linked and non-cross-linked conditions
[0173] Example 5 Preparation of PD-L1 heavy chain antibody
[0174] The Harbour HCAb mouse (Harbour Antibodies BV, WO2010 / 109165A2) is a transgenic mouse carrying a human immunoglobulin repertoire, capable of producing heavy-chain-only antibodies (HCAbs) that are half the size of traditional IgG antibodies. The antibodies produced possess only human heavy-chain variable domains and mouse Fc constant domains. By lacking light chains, these antibodies virtually eliminate the problems of light chain mispairing and heterodimerization, enabling the development of products that are difficult to achieve with traditional antibody platforms.
[0175] Immunization of mice
[0176] Six- to eight-week-old Harbour HCAb mice were immunized multiple times with soluble recombinant human PD-L1-mFc fusion protein (Novo Protein Inc., #CM06). Each mouse received a total dose of 100 μL per immunization, either subcutaneously or intraperitoneally. In the first round of immunization, each mouse received an immunogen consisting of 50 μg of antigen protein mixed with complete Freund's adjuvant (Sigma, #F5881) at a 1:1 volume ratio. In each subsequent booster round, each mouse received 25 μg of antigen protein mixed with Ribi adjuvant (Sigma Adjuvant System, #S6322). Each booster round was separated by at least two weeks, typically with no more than five rounds. Immunizations were performed on days 0, 14, 28, 42, 56, and 70; serum antibody titers were measured on days 49 and 77. Five days before the isolation of HCAb mouse spleen B cells, a final booster immunization was performed at a dose of 25 μg antigen protein per mouse.
[0177] Construction of HCAb library and high-throughput transient expression
[0178] When the PD-L1-specific antibody titer in mouse serum reaches a certain level, the mouse spleen cells are removed to isolate B cells, and CD138-positive plasma cells and human PD-1 antigen-positive B cell populations are sorted using a BD FACS AriaII Cell Sorter. Conventional molecular biological methods are used to amplify human VH genes from plasma cells and B cell populations, and the amplified human VH gene fragments are constructed into a mammalian cell expression plasmid pCAG vector encoding the Fc region sequence of the human IgG1 antibody heavy chain. The plasmid is transfected into mammalian host cells (such as human embryonic kidney cells HEK293) for expression, and a fully human HCAb antibody supernatant is obtained.
[0179] Mirrorball high-throughput screening
[0180] The supernatant expressing HCAb was screened using the Mirrorball high-throughput wash-free antibody screening platform (SPT Labtech). The binding of the supernatant to the CHO-K1 / hPD-L1 (GenScript, #M00543) stable cell line overexpressing human PD-L1 was detected. The positive antibody PR000151 (Atezolizumab analog) was used as a positive control.
[0181] Specifically, CHO-K1 / hPD-L1 cells were washed with serum-free F12K medium (Thermofisher, #21127022) and resuspended to 1×10 6 / mL. Add Draq5 fluorescent probe (CTS, #4048L) (1 μL Draq5 to 1 mL CHO-K1 / hPD-L1 cells, 1:1000 dilution) and incubate in a dark place for 30 minutes. After centrifugation, wash the cells with culture medium and adjust the cell density to 1.0×10 5 cells / mL. Then add the secondary antibody (Alexa 488 AffiniPure Goat Anti-Human IgG, Fcγ Fragment Specific, Jackson ImmunoResearch, #109-545-098). 30 μL of this mixture was added to each well of a 384-well plate (Greiner, #781091). 10 μL of positive control or supernatant expressing HCAb was then added to the 384-well plate and incubated for 2 hours. Fluorescence was read on a Mirrorball.
[0182] The positive antibody supernatants were further identified by FACS detection of binding to CHO-K1 / hPD-L1 cells and ELISA detection of cross-binding activity with cynomolgus monkey PD-L1 protein (Acro biosystems, #PD1-C52H4). The HCAbs obtained by screening were sequenced using conventional sequencing methods to obtain the nucleotide sequence encoding the corresponding VH and the corresponding amino acid sequence. The VH sequence of the HCAb antibody was fused with the human IgG1 heavy chain Fc sequence to obtain a fully human recombinant HCAb antibody molecule.
[0183] Sequence analysis and optimization
[0184] Table 9 lists the preferred recombinant anti-PD-L1 heavy chain antibody molecule PR000960 obtained in this example, as well as the analyzed VH germline gene V gene segments and potential post-translational modification PTM sites. PR000960 has an N-glycosylation modification site in HCDR1, which may affect drugability in later development. To remove this N-glycosylation modification site, PR000960 was subjected to amino acid mutation to obtain the new antibody molecule PR002082 (Table 10).
[0185] Using affinity maturation technology to improve the affinity of binding to PD-L1
[0186] To further improve the affinity of PR002082 for PD-L1, PR002082 was subjected to in vitro affinity maturation. A yeast-displayed antibody mutation library was constructed by random mutagenesis of the CDR regions, and the PR002082 mutation library was screened using the BD FACS AriaIII sorting platform.
[0187] First, mutations were randomly introduced into the three CDRs of PR002082 to establish three yeast display mutation libraries (CDR1, CDR2, and CDR3). These were then enriched using MACS sorting. Subsequently, multiple rounds of sorting using flow cytometry (FACS) were performed to enrich for high-affinity mutant molecules. In the first round, yeast cells with higher binding affinity were sorted using 0.1 nM biotinylated PD-L1-his protein. Culture and induction were then continued. In the second round, yeast cells with higher binding affinity were further sorted using 0.01 nM biotinylated PD-L1-his protein. Culture and induction were then continued. In the third round, the antigen concentration was further reduced during sorting, and 0.003 nM biotinylated PD-L1-his protein was used for the final round of sorting.
[0188] Next, the molecules sorted in the first three rounds are sequenced to identify mutation sites and randomly combine them to create a combinatorial mutation library. FACS is then used to further sort out higher-affinity mutant molecules at lower antigen concentrations.
[0189] The VH variants obtained through affinity maturation were synthesized and cloned into a mammalian cell expression plasmid vector encoding the human IgG1 heavy chain Fc sequence to produce recombinant HCAb antibody molecules. Table 11 lists the variants obtained through affinity maturation of PR002082.
[0190] All mutant molecules (Table 10 and Table 11) were purified into recombinant antibodies according to the method described in 0 and further verified in subsequent functional experiments.
[0191] Table 12 lists the sequences of the PD-L1 antibodies in the present application and the amino acid sequences of the CDRs defined according to the Chothia definition rules. These PD-L1 antibodies include a positive control antibody, the PD-L1 antibody PR000960 of the present invention, and mutant molecules derived therefrom.
[0192] Table 9: Germline gene analysis and PTM site analysis of PD-L1 heavy chain antibodies
[0193] Table 10: PD-L1 heavy chain antibody PR000960 post-translational modification (PTM) variants
[0194] Table 11: Variant molecules obtained by affinity maturation of PR002082
[0195] Table 12: Sequence numbering table of PD-L1 antibody sequences and CDR sequences (Chothia) in the present application
[0196] Example 6 PD-L1 antigen binding protein binds to cells expressing PD-L1
[0197] In this example, flow cytometry (FACS) was used to investigate the binding activity of antibodies or antigen-binding proteins targeting PD-L1 to cells expressing PD-L1. For example, the CHO-K1 cell line CHO-K1 / hPD-L1 (Shanghai Ruizhi Chemical) that overexpresses human PD-L1, the CHO-K1 cell line CHO-K1 / cyPD-L1 (Shanghai Ruizhi Chemical) that overexpresses cynomolgus monkey PD-L1, the lung cancer cell line NCI-H226 (ATCC, #CRL-5826) that overexpresses human PD-L1, and the breast cancer cell line MDA-MB-231 (ATCC, #CRM-HTB-26) that overexpresses human PD-L1.
[0198] Specifically, cells expressing PD-L1 were digested and resuspended in PBS buffer containing 2% BSA. The cell density was adjusted to 1×10 6 100 μL of cells / well were seeded into a 96-well V-bottom plate (Corning, #3894). Then, 100 μL / well of the test antibody was added at a 4-fold dilution, 2x the final concentration. The cells were incubated at 4°C in the dark for 2 hours. Afterwards, the cells were rinsed twice with 100 μL / well of pre-cold PBS containing 2% BSA, centrifuged at 500g for 5 minutes at 4°C, and the supernatant discarded. Then, 100 μL / well of fluorescent secondary antibody (Alexa Fluor 488-conjugated AffiniPure Goat Anti-Human IgG, Fcγ Fragment Specific, Jackson, #109-545-098, 1:500 dilution) was added and incubated at 4°C in the dark for 1 hour. The cells were washed twice with 100 μL / well of pre-cold PBS containing 2% BSA, centrifuged at 500g for 5 minutes at 4°C, and the supernatant discarded. Finally, cells were resuspended in 200 μL / well of pre-chilled PBS buffer containing 2% BSA. Fluorescence and luminescence signals were read using a BD FACS CANTO II flow cytometer or an ACEA NovoCyte flow cytometer, and the data were processed and analyzed using FlowJo v10 software (FlowJo, LLC).
[0199] GraphPad Prism 8 software was used for data processing and graphical analysis. The binding curve of the antibody to the target cell and the EC were obtained by four-parameter nonlinear fitting. 50 Value and other parameters.
[0200] Figures 3A and 3B show the binding curves of PD-L1 heavy chain antibodies PR000960, PR002082 and their variant molecules binding to CHO-K1 / hPD-L1 cells. Table 13 lists the EC values of the corresponding curves. 50 The results showed that the binding ability of PR000960 and PR002082 to human PD-L1 was comparable to that of the control antibody atezolizumab; the affinity matured variant of PR002082 had a slightly better binding ability than PR002082.
[0201] Table 13: PD-L1 antibody binding to CHO-K1 / hPD-L1 cells (corresponding to Figure 3A-3B)
[0202] Example 7 Activity of PD-L1 Antigen Binding Protein in Fluorescent Reporter Gene Assay
[0203] This example uses a Jurkat-NFAT-hPD1 fluorescent reporter cell activation assay (Harbor Biopharma) to investigate the inhibitory effects of PD-L1-targeting antibodies or antigen-binding proteins on the PD-1 signaling pathway. PD-L1 antibodies or antigen-binding proteins block the interaction between PD-L1 and PD-1, thereby relieving PD-1's inhibitory effects on T cells.
[0204] 293T cells 293T-OS8-hPDL1 (Beijing Kangyuan Bochuang, #KC-1148) overexpressing PD-L1 and OS8 (CD3 single-chain antibody transmembrane protein) or Jurkat reporter cells Jurkat-NFAT-hPD1 (Harbor Biopharma) co-expressing PD-1 and NFAT-luciferase reporter genes were cultured and collected; the density of Jurkat-NFAT-hPD1 was adjusted to 1×10 6 cells / mL, the density of 293T-OS8-hPDL1 was 5×10 5 cells / mL. Then take the same volume of cell suspension and mix it, add 100μL / well to a 96-well U-bottom plate, where the ratio of effector cells Jurkat-NFAT-hPD1 to target cells 293T-OS8-hPDL1 is 2:1. Add 50μL / well of pre-gradient diluted antigen binding protein to be tested. Place the 96-well plate in a cell culture incubator at 37℃ 5% CO2 environment and incubate for six hours. Add 50μL / well ONE-Glo TM Luciferase solution (Promega, #E6120) was added and the plate was gently tapped to mix. The reaction was allowed to proceed for 10 minutes at room temperature in the dark. Then 100 μL of the solution was transferred to a 96-well flat-bottom plate (PerkinElmer, #6005225). TMFluorescence values were read on a plate reader (PerkinElmer).
[0205] GraphPad Prism 8 software was used for data processing and graphical analysis. The binding curve of the antibody to the target cell and the EC were obtained by four-parameter nonlinear fitting. 50 Value and other parameters.
[0206] Figures 4A and 4B and Table 14 show that the PD-L1 heavy chain antibodies PR000960, PR002082, and their variants inhibited the PD-1 signaling pathway in a fluorescent reporter gene assay, thereby restoring NFAT signaling in Jurkat cells. The results showed that PR000960 and the control antibody atezolizumab had comparable inhibitory activity; the affinity-matured variant of PR002082 had slightly better inhibitory activity than PR002082.
[0207] Table 14: PD-L1 antibodies inhibit the PD-1 signaling pathway of Jurkat-NFAT-hPD1 (corresponding to Figure 4A and Figure 4B)
[0208] Example 8 Construction of PD-L1×CD40 bispecific antigen binding protein
[0209] In this example, the CD40 antibody from 0 and the PD-L1 heavy chain antibody from 0 were used to construct a PD-L1×CD40 bispecific antigen binding protein with the structure shown in FIG5 .
[0210] As shown in Figure 5 , the Fab end is derived from a conventional antibody A, with VH_A and VL_A representing the heavy and light chain variable regions of antibody A, respectively. The VH end is derived from heavy chain antibody B, with VH_B representing the heavy chain variable region of heavy chain antibody B. CL represents the light chain constant region domain. CH1, CH2, and CH3 represent the first, second, and third domains of the heavy chain constant region, respectively. h represents the hinge region or a derived sequence from an IgG antibody, and L represents a connecting peptide. The binding protein of the illustrated structure comprises two distinct polypeptide chains: a light chain, which, from amino terminus to carboxyl terminus, comprises VL_A-CL; and a heavy chain, which, from amino terminus to carboxyl terminus, comprises VH_B-L-VH_A-CH1-h-CH2-CH3. In certain embodiments, the heavy chain VH_B is directly fused to VH_A, i.e., L has a length of zero. In other embodiments, the heavy chain VH_B is linked to VH_A via a connecting peptide L; L can be a sequence listed in Table 15.
[0211] Table 15: Connector peptide sequences
[0212] In this example, the VH_A and VL_A in Figure 5 are derived from the antigen-binding fragment Fab of the H2L2 (IgG) antibodies PR006495, PR006496, PR006497, PR006504, and PR006511 that bind to CD40; the VH_B is derived from the antigen-binding fragment VH of the heavy chain antibodies PR005878, PR006245, PR006246, PR006247, and PR006248 that bind to PD-L1. Based on these PD-L1 and / or CD40 antigen-binding fragments, several PD-L1×CD40 bispecific antigen-binding proteins (listed in Table 16) with the structures shown in Figure 5 were constructed. These molecules all have similar structures and utilize human IgG1 constant region sequences; to eliminate Fc-mediated effector functions such as ADCC, three amino acid mutations, L234A / L235A / G237A (Eu encoding), were introduced into the Fc region. Table 18 lists the sequence numbers of the PD-L1×CD40 polypeptide chain amino acid sequences. Protein samples were prepared and analyzed for these PD-L1×CD40 molecules according to the method described in [0], as summarized in Table 17. The PD-L1×CD40 molecules constructed in this example all had high yields and purities (see Example 1 for methods for detecting the expression and purity of PD-L1×CD40 molecules), with the purity of most protein samples exceeding 95%.
[0213] Table 16: PD-L1×CD40 bispecific antigen binding proteins of the present invention
[0214] Table 17: Transient expression of PD-L1×CD40 bispecific antibody molecules
[0215] Table 18: Sequence numbering table of the polypeptide chains of the PD-L1×CD40 bispecific antibody molecules of the present invention
[0216] Example 9 PD-L1×CD40 Binding to Cells Expressing PD-L1 or CD40
[0217] In this example, the method described in 0 and 0 was used to test the binding ability of the PD-L1×CD40 bispecific binding protein to various cells expressing PD-L1 or CD40. These cells include: CHO-K1 cells that do not express PD-L1 or CD40, the CHO-K1 cell line CHO-K1 / hPD-L1 (Shanghai Ruizhi Chemical) that highly expresses human PD-L1, the CHO-K1 cell line CHO-K1 / cyPD-L1 (Shanghai Ruizhi Chemical) that highly expresses cynomolgus monkey PD-L1, the CHO-K1 cell line CHO-K1 / hCD40 (Shanghai Ruizhi Chemical) that highly expresses human CD40, the CHO-K1 cell line CHO-K1 / cyCD40 (Shanghai Ruizhi Chemical) that highly expresses cynomolgus monkey CD40, the lymphoma cells Raji (ATCC, #CCL-86) that highly express human CD40, the lung cancer cells NCI-H226 (ATCC, #CRL-5826) that highly express human PD-L1, and the breast cancer cells MDA-MB-231 (ATCC, #CRM-HTB-26) that highly express both human PD-L1 and CD40.
[0218] Table 19 summarizes the results of the binding of PD-L1×CD40 bispecific binding protein and control molecules to various cells. The corresponding legend shows the binding curve of the antigen binding protein binding to the target cells, and the corresponding table lists the binding parameters (EC 50 Figures 10A and 10B show that PD-L1×CD40 does not bind to CHO-K1 cells. Figures 6A and 6B and Table 20 show that PD-L1×CD40 binds to CHO-K1 / hPD-L1 cells. Figures 7A and 7B and Table 21 show that PD-L1×CD40 binds to cynomolgus monkey PD-L1 cells. Figures 8A and 8B and Table 22 show that PD-L1×CD40 binds to CHO-K1 / hCD40 cells. Figures 9A and 9B and Table 23 show that PD-L1×CD40 binds to cynomolgus monkey CD40 cells. Figures 11A and 11B and Table 24 show that PD-L1×CD40 binds to NCI-H226 cells. Figures 12A and 12B and Table 25 show that PD-L1×CD40 binds to Raji cells. Figures 13A and 13B and Table 26 show PD-L1 x CD40 binding to MDA-MB-231 cells.
[0219] The results showed that all PD-L1×CD40 bispecific antibodies could efficiently bind to PD-L1 expressing cell lines, such as CHO-K1 / hPD-L1 (EC 50 About 1nM), CHO-K1 / cy PD-L1 (EC 50 Less than 1 nM) and NCI-226 (EC 50Less than 1 nM), and its binding activity was comparable to that of the positive reference Atezolizumab; the PD-L1×CD40 dual antibody did not bind to CHO-K1 cells that did not express the target; the PD-L1×CD40 dual antibody also efficiently bound to MDA-MB-231 cells (EC 50 less than 1 nM), and its binding was significantly stronger than that of the positive reference Atezolizumab (higher MFI signal).
[0220] Moreover, all PD-L1×CD40 bispecific antibodies could efficiently bind to CD40-expressing cell lines, such as CHO-K1 / hCD40 (EC 50 About 1-2nM), CHO-K1 / cyCD40 (EC 50 about 1-4nM) and Raji (EC 50 The binding activity of the PD-L1×CD40 dual antibody was about 1-2 nM, and was stronger or equivalent to that of the positive reference Selicrelumab. The PD-L1×CD40 dual antibody also efficiently bound to MDA-MB-231 cells, and its binding effect was significantly stronger than that of the positive reference Selicrelumab.
[0221] Table 19: Figure showing the cell lines used in this example and the corresponding FACS binding test data
[0222] Table 20: PD-L1×CD40 binding to CHO-K1 / hPD-L1 cells (corresponding to Figure 6A and Figure 6B)
[0223] Table 21: PD-L1×CD40 binding to CHO-K1 / cyPD-L1 cells (corresponding to Figure 7A and Figure 7B)
[0224] Table 22: PD-L1×CD40 binding to CHO-K1 / hCD40 cells (corresponding to Figure 8A and Figure 8B)
[0225] Table 23: PD-L1×CD40 binding to CHO-K1 / cyCD40 cells (corresponding to Figure 9A and Figure 9B)
[0226] Table 24: PD-L1×CD40 binding to NCI-H226 cells (corresponding to Figures 11A and 11B)
[0227] Table 25: PD-L1×CD40 binding to Raji cells (corresponding to Figures 12A and 12B)
[0228] Table 26: PD-L1×CD40 binding to MDA-MB-231 cells (corresponding to Figures 13A and 13B)
[0229] Example 10 PD-L1×CD40 inhibits PD-1 signaling pathway in a fluorescent reporter gene assay
[0230] This example uses the method described in 0 to test the inhibitory effect of PD-L1×CD40 bispecific binding proteins on the PD-1 signaling pathway. The results are shown in Figures 14A-14D and Table 27. All PD-L1×CD40 bispecific antibodies can effectively block the PD-1 / PD-L1 interaction and activate TCR and NFAT signals, with activity comparable to that of the positive reference antibody Atezolizumab (EC 50 about 0.1-0.3nM).
[0231] Table 27: PD-L1×CD40 inhibits the PD-1 signaling pathway of Jurkat-NFAT-hPD1 (corresponding to Figures 14A-14D)
[0232] Example 11 Activation of CD40 Signaling Pathway by PD-L1×CD40 in Fluorescence Reporter Gene Assay
[0233] This example uses the method described in [0] to test the CD40 activation effect of the PD-L1×CD40 bispecific binding protein under PD-L1-mediated crosslinking and without crosslinking. CHO-K1 / hPD-L1 cells, which overexpress PD-L1, were used to crosslink the test molecule to investigate whether crosslinking could further enhance CD40 activation. In this experiment, CHO-K1 / hPD-L1 cells overexpressing PD-L1 could crosslink the PD-L1×CD40 bispecific binding protein with PD-L1, while CHO-K1 cells that do not express PD-L1 or CD40 were unable to bind the test molecule. The test molecule was tested for activation of the HEK293-hCD40-NFκB reporter gene system after incubation with CHO-K1 / hPD-L1 cells or with CHO-K1 cells.
[0234] The results shown in Figures 15A-15K and Table 28 indicate that the CD40 antibody Selicrelumab can activate the downstream signaling pathway of CD40, and this activation is independent of the presence of exogenous cross-linking. 50 About 0.2nM. However, PD-L1×CD40 dual antibodies, such as PR007151 and PR007619, under the condition of PD-L1 cross-linking (EC 50The activation effect on the downstream signaling pathway of CD40 was significantly stronger than that without PD-L1 cross-linking (EC 50 The results of other experiments, such as those on PR006919 and PR007070, and those on PR007268, PR007269, PR007273, PR007275, and PR007276, were similar, indicating that the PD-L1×CD40 bispecific antibody can better activate the CD40 downstream signaling pathway by cross-linking PD-L1 with CD40.
[0235] Table 28: CD40 signaling pathway activated by PD-L1×CD40 in HEK293-hCD40-NFκB under cross-linked and non-cross-linked conditions (corresponding to Figures 15A-15K)
[0236] Example 12 Activation of DC Cells by PD-L1×CD40
[0237] This example studies the activation effect of PD-L1×CD40 bispecific binding protein on dendritic cells (DCs) under PD-L1-mediated cross-linking and non-cross-linking conditions.
[0238] This example uses PBMC-derived monocytes induced into DCs for activation experiments. First, monocytes were isolated from PBMCs using a human CD14 isolation kit (Miltenyi, #130-050-201), cultured with RPMI1640 complete medium, and induced for six days with 50 ng / mL IL-4 (R&D Systems, #204-IL) and 100 ng / mL GM-CSF (R&D Systems, #215-GM) cytokines to generate immature dendritic cells (iDCs). Half of the iDCs were induced with 1 μg / mL LPS (Sigma, #L2880-10MG) for 24 hours to become mature dendritic cells (mDCs). mDCs from donors #1 and #2 were used directly after induction with LPS for 24 hours; mDCs from donor #4 were used after LPS was washed away and re-incubated with RPMI1640 complete medium and 50 ng / mL IL-4 and 100 ng / mL GM-CSF cytokines for 24 hours.
[0239] The day before mDC induction, CHO-K1 and CHO-K1 / hPD-L1 cells were seeded in 96-well flat-bottom plates (Corning, #3599). CHO-K1 and CHO-K1 / hPD-L1 cells were first harvested and incubated at 37°C for 1 hour to inhibit cell proliferation. After washing, the cell density was adjusted to 1×10 cells / well using F-12K complete medium. 5 cells / mL, 100 μL / well, added to a 96-well flat-bottom plate, and finally placed in a cell culture incubator overnight. The next day, the antibody to be tested was diluted to 2 times the final concentration with RPMI1640 complete medium, and then diluted 10 times or 3 times. Selicrelumab and hIgG1 were used as positive and negative controls, respectively. After discarding the culture medium of CHO-K1 and CHO-K1 / hPD-L1 cells, 100 μL / well of antibody was added. iDCs and mDCs were then collected and the cell density was adjusted to 5×10 5 Cells were plated at 100 μL / well and mixed with the test antibodies at 100 μL / well. The cells were then incubated in a cell culture incubator. Three days later, cell supernatants were collected and IL-12p40 secretion levels were measured using a human IL-12 / -23 (p40) ELISA kit (MABTECH, #3450-1H-20). GraphPad Prism 8 software was used for data processing and graphical analysis, showing IL12p40 secretion levels in relation to antibody concentration.
[0240] In this example, the PD-L1×CD40 bispecific antibody was tested multiple times using DCs from multiple donors. The results are shown in Figures 16A and 16B, Figures 17A and 17B, Figures 18A and 18B, and Figures 19A-19D. Table 29 summarizes the key experimental parameters corresponding to each figure, such as the DC source, target cells used for crosslinking, and the molecules tested.
[0241] Results showed that the positive reference antibody, selicrelumab, effectively activated both iDCs and mDCs, an effect unaffected by the presence of the tumor antigen PD-L1. PD-L1 × CD40 bispecific antibodies, such as PR006919, PR007070, and PR007151, conditionally activated both iDCs and mDCs; that is, they efficiently activated DCs in the presence of PD-L1 crosslinking, but exhibited low or no activation in the absence of PD-L1 crosslinking. This selective activation of the PD-L1 × CD40 bispecific antibody is not possessed by selicrelumab and provides a foundation for the efficient and safe efficacy of bispecific antibodies. Furthermore, in some experiments with donor DCs, the activation effect of the PD-L1 × CD40 bispecific antibody was significantly stronger than that of selicrelumab, as shown in Figures 17A and 17B.
[0242] Table 29: Figures corresponding to different batches of DC activation experiments in this example
[0243] Example 13 Activation of B cells by PD-L1×CD40
[0244] This example studies the effect of PD-L1×CD40 bispecific binding protein on B cell proliferation with and without PD-L1-mediated cross-linking.
[0245] CHO-K1 and CHO-K1 / hPD-L1 cells were seeded in 96-well flat-bottom plates (Corning, #3599) one day in advance. CHO-K1 and CHO-K1 / hPD-L1 cells were harvested and incubated at 37°C for 1 hour to inhibit cell proliferation. After washing, the cell density was adjusted to 1×10 cells / well using F-12K complete medium. 5 cells / mL, added to a 96-well flat-bottom plate at 100 μL / well and placed in a cell culture incubator overnight. The next day, the antibody to be tested was diluted to 2 times the final concentration with RPMI1640 complete medium, and then diluted 10 times in series; Selicrelumab and hIgG1 were used as positive and negative controls; the working concentrations of the antibody to be tested were 100 nM, 10 nM and 1 nM. After discarding the culture medium of CHO-K1 and CHO-K1 / hPD-L1 cells, the antibody was added at 100 μL / well. B cells were then sorted from donor PBMCs using a human CD19 sorting kit (Miltenyi, #130-050-301); 1 μM CFSE (Invitrogen, #34554) was added and labeled at 37°C for 20 minutes; after washing twice, the cell density was adjusted to 1×106 Cells were diluted 100 μL / well in a 96-well plate with the test antibody and then cultured in a cell culture incubator. Six days later, cells were transferred to a 96-well U-bottom plate (Corning, #3799) and centrifuged at 500g for 4 minutes at 4°C. The supernatant was discarded and 100 μL / well of dead cell dye (Invitrogen, #L34976A, 1:1000 dilution) was added. The cells were incubated at 4°C in the dark for 15 minutes. The cells were washed twice with 200 μL / well of PBS and resuspended in 100 μL of Fc Block antibody (BD, #564220, 1:50 dilution). The cells were incubated at 4°C in the dark for 15 minutes. Subsequently, 2 μL of anti-human CD19 antibody (Biolegend, #302234) was added to each well and incubated at 4°C in the dark for 30 minutes. The cells were washed twice with 200 μL / well of 2% FBS-PBS and resuspended in 100 μL of 2% FBS-PBS. Fluorescence signals were read using a BD FACS CANTO II flow cytometer. Data were processed and analyzed using GraphPad Prism 8 software.
[0246] In this example, the PD-L1×CD40 bispecific antibody was tested multiple times using B cells from multiple donors. The results are shown in Figures 20A and 20B, Figures 21A and 21B, Figures 22A and 22B, Figures 23A and 23B, and Figures 24A and 24B. Table 30 summarizes the key experimental parameters corresponding to each figure, such as the B cell source, target cells used for crosslinking, and the molecules tested.
[0247] The results showed that the positive reference antibody, selicrelumab, effectively promoted B cell proliferation, but this effect was unaffected by the presence of the tumor antigen PD-L1. PD-L1 × CD40 bispecific antibodies, such as PR006919, PR007070, and PR007151, conditionally promoted B cell proliferation; that is, they effectively promoted B cell proliferation in the presence of PD-L1 crosslinking, but had little or no effect in the absence of PD-L1 crosslinking. This selective activation property of the PD-L1 × CD40 bispecific antibody is not possessed by selicrelumab and provides a foundation for the efficient and safe efficacy of bispecific antibodies. Furthermore, in some donor B cell proliferation experiments, the proliferation-promoting effect of the PD-L1 × CD40 bispecific antibody was significantly greater than that of selicrelumab, as shown in Figures 24A and 24B.
[0248] Table 30: Figures corresponding to the B cell proliferation experiments of different batches in this example
[0249] Example 14 Study on the Anti-tumor Efficacy and Safety of PD-L1×CD40
[0250] This example investigates the antitumor efficacy of the PD-L1×CD40 bispecific binding protein in the hPD1×hCD40-C57BL / 6J mouse MC38-hPDL1 tumor model. MC38-hPDL1 cells are MC38 mouse colon cancer cells that overexpress human PD-L1. hPD1×hCD40-C57BL / 6J mice are PD1 / CD40 humanized transgenic mice (provided by Shanghai South Model Organisms Technology Co., Ltd.) that have had the human PD-1 and human CD40 genes knocked into C57BL / 6J mice.
[0251] MC38-hPDL1 cells were cultured in a 37°C, 5% CO2 incubator in DMEM containing 10% inactivated fetal bovine serum. Cells were subcultured every 3 to 4 days after confluence. MC38-hPDL1 cells in the logarithmic growth phase were collected, resuspended in PBS, and counted. The cell concentration was adjusted to 1.0 × 10 7 / mL; The cell suspension was inoculated subcutaneously in the right flank of hPD1×hCD40-C57BL / 6J mice using a 1mL syringe, 100μL / mouse, and approximately 1.0×10 6 When the average tumor volume reached a certain level, mice with moderate tumor volumes were selected and randomly assigned to experimental groups based on tumor volume, with N mice per group. Dosing began on the day of grouping and was administered twice weekly (BIW) for a total of seven times via intraperitoneal injection. Tumor volume was measured on the day of dosing, and mouse weight was recorded.
[0252] Example 14.1 Mouse efficacy experiment #1
[0253] In the first experiment, when the average tumor volume reached 110 mm 3 At the same time, mice with moderate tumor volumes were selected and grouped and dosed according to the schedule in Table 31.
[0254] Table 31: Experimental design and tumor inhibition rate of each drug group
[0255] The results are shown in Figures 25A and 25B. On day 21 after the start of administration, the average tumor volume of the control group Group 1 (Isotype) was 2210.35±487.58 mm 3The tumor volumes of Group 2 (Selicrelumab), Group 4 (Selicrelumab+Atezolizumab), Group 5 (PR007070), and Group 6 (PR007151) were 239.07±73.25 mm, respectively. 3 、52.33±18.99mm 3 、647.92±176.36mm 3 and 507.58±116.91mm 3 The corresponding tumor inhibition rates were 93.89%, 102.78%, 74.41% and 81.10%, respectively, which were significantly different from those in Group 1 (Isotype) (P<0.01). The tumor volumes of Group 3 (Atezolizumab) were 1563.33±325.77mm 3 , the tumor inhibition rate was 30.81%.
[0256] On day 3 after dosing, mice in Group 2 (Selicrelumab) and Group 4 (Selicrelumab + Atezolizumab) showed a significant decrease in body weight (nearly 10%), while mice in Group 3 (Atezolizumab) maintained normal weight. This suggests that Selicrelumab has significant side effects and toxicity that cause significant weight loss in mice. In contrast, mice in Groups 5 (PR007070) and 6 (PR007151) of the PD-L1×CD40 dual antibody group maintained normal weight, indicating a good safety profile.
[0257] These results indicate that the PD-L1×CD40 dual antibodies PR007070 and PR007151 have significant anti-tumor activity and are significantly superior to atezolizumab. Furthermore, based on changes in mouse body weight, the safety profile of the PD-L1×CD40 dual antibodies PR007070 and PR007151 is significantly superior to that of selicrelumab and the combination of selicrelumab and atezolizumab.
[0258] Example 14.2 Mouse efficacy experiment #2
[0259] In the second experiment, when the average tumor volume reached 89 mm 3 At the same time, mice with moderate tumor volumes were selected and grouped and dosed according to the schedule in Table 32.
[0260] Table 32: Experimental design and tumor inhibition rate of each drug group
[0261] The results are shown in Figures 26A and 26B. On day 18 after the start of administration, the average tumor volume of the control group Group 1 (hIgG1, 10 mg / kg) was 1927.77±200.44 mm 3 The tumor volumes of Group 2 (PR007619, 12 mg / kg) and Group 3 (PR007619, 6 mg / kg) were 333.00 ± 103.06 mm 3 、538.85±224.35mm 3 The corresponding tumor inhibition rates were 82.73% and 72.05%, respectively. The tumor volumes of Group 4 (PR007281, 12 mg / kg) and Group 5 (PR007281, 6 mg / kg) were 602.40±278.52 mm 3 、68.66±11.68mm 3 The corresponding tumor inhibition rates were 68.75% and 96.44%, respectively. The tumor volumes of Group 6 (PR007556, 12 mg / kg) and Group 7 (PR007556, 6 mg / kg) were 347.56±167.80 mm 3 、258.51±102.12mm 3 The corresponding tumor inhibition rates were 81.97% and 86.59%, respectively. The tumor volumes of Group 8 (PR007276, 12 mg / kg) and Group 9 (PR007276, 6 mg / kg) were 200.34±59.12 mm 3 、58.33±42.67mm 3 The corresponding tumor inhibition rates were 88.57% and 96.97%, respectively. Throughout the experiment, the body weight of the mice in the drug-treated groups remained normal, and the drug had no significant effect on the mice's condition.
[0262] The above results show that the PD-L1×CD40 bispecific antibodies PR007619, PR007281, PR007556, and PR007276 all exhibit excellent anti-tumor activity and safety.
[0263] Example 14.3 Mouse efficacy experiment #3 and mouse liver toxicity study
[0264] In the third experiment, when the average tumor volume reached 85 mm 3 At the same time, mice with moderate tumor volumes were selected and grouped and dosed according to the schedule in Table 33.
[0265] Twenty-four hours after the final administration, serum samples from each group (36 total) were collected for biochemical analysis, including the levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Liver tissue from 36 mice was also collected and paraffin-embedded. Six consecutive sections of each liver tissue were sliced and stained with H&E. Finally, three stained sections were selected for scanning and microscopic analysis.
[0266] Table 33: Experimental design and tumor inhibition rate of each drug group
[0267] The antitumor efficacy results are shown in Figures 27A and 27B. On day 22 after the start of administration, the tumor volume of the control group Group 1 (hIgG1, 3.6 mg / kg) was 1865.24±125.47 mm 3 The tumor volumes of Group 2 (PR007619, 1.8 mg / kg), Group 3 (PR007619, 3.6 mg / kg), Group 4 (PR007619, 6 mg / kg), and Group 5 (PR007619, 10.8 mg / kg) were 1177.74±198.47 mm, respectively. 3 、829.01±164.87mm 3 、708.84±208.76mm 3 、541.99±41.2mm 3 The corresponding tumor inhibition rates were 36.86%, 55.55%, 62%, and 70.94%, respectively. The tumor volume of Group 6 (Selicrelumab, 5 mg / kg) was 339.68±72.9 mm 3 , corresponding to a tumor inhibition rate of 81.79%. Throughout the experiment, the body weight of mice in the hIgG1 control group and the PR007619-treated group remained normal, with no significant effect from the drug. However, mice in the selicrelumab-treated group experienced some weight loss, suggesting that selicrelumab has certain side effects and toxicity.
[0268] These results demonstrate that the PD-L1×CD40 dual-antibody PR007619 exhibits dose-dependent tumor suppressive activity with significant inhibitory effects. Furthermore, PR007619 has a better safety profile than the control molecule, selicrelumab.
[0269] The results of blood biochemical index testing are shown in Figure 28. The average ALT values for Groups 1–6 were 34±8.83 U / L, 46±24.64 U / L, 34.5±7.04 U / L, 32.5±9.38 U / L, 31.5±1.64 U / L, and 128.7±76.2 U / L, respectively. Group 6 (5 mg / kg selicrelumab) showed a significant increase compared to Group 1 (control group) (P=0.0128). However, Groups 2–5 (different doses of PR007619) showed no significant differences compared to Group 1 (control group). Similarly, the mean AST values for Groups 1–6 were 180±40.3 U / L, 197.5±95.9 U / L, 120.5±41.2 U / L, 120±61.3 U / L, 123.5±16.69 U / L, and 326.17±153.6 U / L, respectively. Group 6 (5 mg / kg selicrelumab) showed a significant increase compared with Group 1 (control group) (P=0.0478). However, there were no significant differences between Groups 2–5 (different doses of PR007619) and Group 1 (control group).
[0270] As shown in Figure 29, the liver tissue of mice in Group 6 (Selicrelumab, 5 mg / kg) showed significant damage, manifested by moderate multifocal infiltration of mononuclear cells and lymphocytes in the portal vein; moderate multifocal Kupffer cell proliferation in the sinusoids; significant increase and diffusion of sinusoidal mononuclear cells; and significant multifocal hepatocyte degeneration and necrosis. No significant pathological changes were observed in the liver tissue of mice in Group 1 (control group) and Groups 2–5 (groups treated with different doses of PR007619).
[0271] The above blood biochemical indicators and tissue section results all show that the CD40 monoclonal antibody Selicrelumab caused significant acute hepatotoxicity in hPD1×hCD40-C57BL / 6J transgenic mice; while the PD-L1×CD40 bispecific antibody PR007619 showed excellent safety.
[0272] Example 14.4 Mouse efficacy experiment #4 and mouse liver toxicity study
[0273] The fourth experiment aimed to study the effects of PD-L1×CD40 dual antibodies on mice, including the inhibition of tumor growth, changes in mouse body weight, changes in serum cytokine levels, and changes in hepatotoxicity blood biochemical indicators.
[0274] In the fourth experiment, when the average tumor volume reached 82 mm 3 At the same time, mice with moderate individual tumor volumes were selected and grouped and dosed according to the scheme in Table 34. Each group consisted of 10 mice (5 female mice and 5 male mice). Dosing began on the day of grouping and was administered twice a week (BIW) for a total of 4 doses (days 0, 3, 7, and 10). The route of administration was intraperitoneal injection. Tumor volume was measured during the period (days 0, 2, 5, 9, and 11). 24 hours after the first dose, serum was collected for testing of cytokine levels (IL-6, TNF-α, IFN-γ, and IL12p40). 24 hours after the last dose, serum was collected for blood biochemical testing of hepatotoxicity indicators (ALT and AST). Finally, mouse liver tissues (50 in total) were collected and embedded in paraffin. After 6 consecutive sections of each liver tissue were sliced, H&E staining was performed, and finally three stained sections were selected for scanning and microscopic analysis. In addition to the liver, the heart, spleen, lung, and kidney of the mice were also collected for paraffin embedding and section staining analysis.
[0275] Table 34: Experimental design and tumor inhibition rate of each drug group
[0276] The antitumor efficacy results are shown in Figures 30A and 30B. On the 11th day after the start of administration, the average tumor volume of the control group Group 1 (hIgG1, 10 mg / kg) was 1653.68±153.10 mm 3 The tumor volumes of Group 2 (PR007619, 12 mg / kg), Group 3 (Selicrelumab, 1 mg / kg), Group 4 (Selicrelumab, 2.5 mg / kg), and Group 5 (Selicrelumab, 5 mg / kg) were 552.96±123.59 mm, respectively. 3 、542.23±79.83mm 3 、350.60±61.35mm 3 and 272.65±45.48mm 3 , the corresponding tumor inhibition rates were 66.56%, 67.21%, 78.80% and 83.51%, respectively. There were statistical differences between each dosing group and Group 1 (P>0.05). On the other hand, the body weight results showed that Group 2 (PR007619, 12 mg / kg) had no significant effect on the body weight of mice; each dose group of Selicrelumab (Group 3-5) caused the mice to lose weight after administration, with the degree of decrease close to or exceeding 10%, and the higher the dose, the more difficult it was to restore the body weight. In particular, the body weight of the medium and high dose groups of Selicrelumab was never restored after administration.
[0277] The above results show that PD-L1×CD40 dual antibody has significant anti-tumor efficacy and safety, while Selicrelumab causes weight loss in mice and exhibits significant toxic side effects.
[0278] Table 35: Blood biochemical indicators ALT and AST levels
[0279] The results of blood biochemical index tests are shown in Figure 31 and Table 35. The corresponding ALT values of Group 1–Group 5 were 168.3±79.8 U / L, 107.6±54.2 U / L, 105.1±44.8 U / L, 310±189.3 U / L, and 507.6±150.0 U / L, respectively; the corresponding AST values of Group 1–Group 5 were 51.6±69.1 U / L, 19.7±7.26 U / L, 31±19.1 / L, 96.5±86.1 U / L, and 147.7±73.1 U / L, respectively. In Group 5 (Selicrelumab, 5 mg / kg) compared to the Group 1 control group, ALT and AST levels were significantly increased (P < 0.001). A significant difference was also observed in ALT between Group 4 (Selicrelumab, 2.5 mg / kg) and the Group 1 control group (P = 0.037). However, there were no significant differences in ALT or AST between Group 2 (PR007619, 12 mg / kg) and the Group 1 control group. This suggests that Selicrelumab causes a significant increase in the hepatotoxic blood biochemical indicators ALT and AST, while the PD-L1×CD40 dual antibody does not cause an increase in ALT and AST levels in mouse serum.
[0280] Table 36: Peripheral blood cytokine levels
[0281] The peripheral blood cytokine test results are shown in Figures 32 and 33 and Table 36. The corresponding cytokine IL-6 values of Group 1–Group 5 were 16.3±8.74 pg / mL, 24.8±11.7 pg / mL, 1343.8±529.5 pg / mL, 1428.2±569.5 pg / mL, and 2038.0±747.2 pg / mL, respectively; the corresponding cytokine IFN-γ values of Group 1–Group 5 were 0.54±0.19 pg / mL, 1.48±0.98 pg / mL, 159.0±90.9 pg / mL, 138.9±91.7 pg / mL, and 147.4±79.44 pg / mL, respectively; The corresponding cytokine TNF-α values of the 5 groups were 14.1±3.79 pg / mL, 17.3±8.08 pg / mL, 1186.1±255.7 pg / mL, 1274.7±392.3 pg / mL and 1311.5±179.9 pg / mL, respectively; the corresponding cytokine IL12p40 values of Group 1–Group 5 were 1157.1±125.8 pg / mL, 1786.8±369.5 pg / mL, 92119.7±30959.2 pg / mL, 99263.0±24254.9 pg / mL and 110786.1±21607.5 pg / mL, respectively.
[0282] Thus, in terms of cytokine IL-6, TNF-α, and IFN-γ levels, all dose groups of selicrelumab (Groups 3-5) can cause a significant increase in cytokine levels, showing extremely significant differences compared with the Group 1 control group (P < 0.0001); while the PD-L1 × CD40 dual antibody (Group 2) group did not cause an increase in cytokine levels, and there was no significant difference compared with the Group 1 control group (P > 0.05). In addition, in terms of cytokine IL12p40 levels, all dose groups of selicrelumab (Groups 3-5) can cause a significant increase in IL12p40 levels, showing extremely significant differences compared with the Group 1 control group (P < 0.0001); while the PD-L1 × CD40 dual antibody (Group 2) only caused a small increase in IL12p40 (P = 0.0004). The combined results showed that Selicrelumab caused significant cytokine release syndrome in the peripheral blood of mice, while PD-L1×CD40 dual antibody did not.
[0283] The results of liver tissue sections are shown in Figure 34. In Group 1, the livers of all 10 animals were within normal limits. In Group 2, only one animal, B5784, had a small amount of multifocal perivascular lymphocytic infiltration, while the livers of the other 9 animals were within normal limits. In Group 3, the livers of all 10 animals had minimal, mild, or very mild multifocal perivascular lymphocytic infiltration. In Group 4, the liver of animal A5757 had moderate multifocal perivascular lymphocytic infiltration, while the livers of the other animals had moderate multifocal granulomatous inflammation (monocyte infiltration with fibrosis, mostly lymphocytes and macrophages) around the blood vessels or venous sinuses. In Group 5, the livers of all animals had moderate to significant multifocal granulomatous inflammation (monocyte infiltration with fibrosis, mostly lymphocytes and macrophages) around the blood vessels or venous sinuses.
[0284] In this study, the PD-L1 × CD40 dual-antibody (Group 2) resulted in minimal or mild changes in the liver, kidneys, lungs, and spleen compared with the control group (Group 1). Minimal lymphocytic infiltration was a predictable pharmacodynamic response. Selicrelumab dose groups (Groups 3, 4, and 5) showed more adverse changes in these tissues compared with the control group (Group 1). These tissues showed tubular degeneration, increased lymphocytic infiltration, and / or inflammation. This exaggerated the predictable pharmacodynamic response and could be harmful to the animals. Therefore, the PD-L1 × CD40 dual-antibody resulted in a less severe and less frequent lesion than did selicrelumab.
[0285] In summary, Selicrelumab caused severe cytokine release syndrome in mice, increased hepatotoxicity serum indicators, and damage to the liver and other organ tissues; while the PD-L1×CD40 dual antibody not only had strong anti-tumor efficacy but also had excellent safety, did not cause cytokine release syndrome, did not cause increased hepatotoxicity serum indicators, and did not cause damage to the liver and other organ tissues.
[0286] Example 15 Pharmacokinetic Evaluation of PD-L1×CD40
[0287] This example studies the pharmacokinetic properties of four bispecific binding protein molecules with similar sequences and identical structures in mice.
[0288] Dosing and Blood Collection: For each test binding protein molecule, six female C57BL / 6J mice weighing 18-22 grams were administered intravenously at a dose of 6 mg / kg. Whole blood was collected from one group of three mice 5 minutes, 24 hours (day 1), day 4, and day 10 after dosing. Whole blood was collected from another group of three mice before dosing and 5 hours, day 2, day 7, and day 14 after dosing. Whole blood was allowed to clot and then centrifuged. Serum samples were frozen at -80°C until analysis.
[0289] Analytical Methods: Two ELISA methods were used to quantify drug concentrations in mouse serum. ELISA method 1, the Fc-terminal detection method, uses a goat anti-human Fc polyclonal antibody (ROCKLAND, #609-101-017) coated on a 96-well plate to capture antibodies containing human Fc in mouse serum. These antibodies are then detected using an HRP-conjugated goat anti-human Fc secondary antibody (Jackson, #109-035-098). ELISA method 2, the functional domain detection method, uses a PD-L1 antigen protein (Novoprotein, #C315) coated on a 96-well plate to capture antibodies specifically recognizing the PD-L1 antigen in mouse serum. These antibodies are then detected using an HRP-conjugated goat anti-human Fc secondary antibody (Jackson, #109-035-098). Pharmacokinetic parameters were analyzed using Phoenix WinNonlin software version 8.2, using a non-compartmental model (NCA).
[0290] As shown in Table 37, the bispecific antibody molecule PR007556 has a serum half-life t1 / 2 value similar to that of conventional IgG antibodies, and the PD-L1 end detection method shows that its t1 / 2 value is 10.3 days. The bispecific antibody molecules PR007619, PR007281 and PR007276 have similar pharmacokinetics to conventional IgG antibodies: under the Fc end detection method, the serum half-life of PR007619, PR007281 and PR007276 in mice is t 1 / 2 The values were approximately 13.6 days, 15.1 days and 15.7 days, respectively; under the PD-L1 end detection method, the serum half-life t1 / 2 values of PR007619, PR007281 and PR007276 in mice were approximately 13.5 days, 18.1 days and 13.7 days, respectively.
[0291] Table 37: Pharmacokinetic parameters of PD-L1×CD40 in mice
[0292] The results are shown in Table 37 and Figures 35A-35D. These PD-L1×CD40 bispecific antibodies have serum half-life t1 / 2 values similar to those of conventional IgG antibodies. Depending on the detection method, their T 1 / 2 The value is 10 days to 20 days.
[0293] Although the above describes specific embodiments of the present invention, it should be understood by those skilled in the art that these are merely illustrative and that various changes or modifications may be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. An antigen binding protein targeting PD-L1 and CD40, comprising a first protein functional region and a second protein functional region, characterized in that: The first protein functional region comprises an antigen binding protein targeting CD40, and the second protein functional region comprises an antigen binding protein targeting PD-L1; wherein, The antigen-binding protein targeting CD40 comprises a light chain variable region (VL) and a heavy chain variable region (VH), the VL comprising LCDR1, LCDR2 and LCDR3, and the VH comprising HCDR1, HCDR2 and HCDR3; the LCDR1 comprises the amino acid sequence shown in SEQ ID NO:38, the LCDR2 comprises the amino acid sequence shown in SEQ ID NO:43, and the LCDR3 comprises the amino acid sequence shown in SEQ ID NO:48 or a variant 3 having 3, 2 or 1 amino acid mutations in SEQ ID NO:48; the HCDR1 comprises the amino acid sequence shown in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO:18, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO:
27.
2. The antigen binding protein targeting PD-L1 and CD40 according to claim 1, wherein The variant 3 comprises an amino acid sequence having a PTM site mutation in the amino acid sequence of SEQ ID NO:48, preferably an amino acid sequence having an amino acid mutation at position 4 and / or 5 of the amino acid sequence of SEQ ID NO:48, wherein the amino acid mutation is preferably an amino acid substitution, more preferably a conservative amino acid substitution; preferably, the variant 3 is an amino acid sequence having N4A / F / Y / V / N and / or S5N mutations in the amino acid sequence of SEQ ID NO:48; more preferably, the variant 3 is an amino acid sequence as shown in any one of SEQ ID NOs:49-53; further more preferably, in the antigen-binding protein targeting CD40, the LCDR1 comprises the amino acid sequence as shown in SEQ ID NO:38, the LCDR2 comprises the amino acid sequence as shown in SEQ ID NO:43, and the LCDR3 comprises the amino acid sequence as shown in any one of SEQ ID NOs:48-53; the HCDR1 comprises the amino acid sequence as shown in SEQ ID NO:8, the HCDR2 comprises the amino acid sequence as shown in SEQ ID NO:18, and the HCDR3 comprises the amino acid sequence as shown in SEQ ID NO: The amino acid sequence shown in NO:
27.
3. The antigen binding protein targeting PD-L1 and CD40 according to claim 1 or 2, characterized in that In the antigen-binding protein targeting CD40, the VL comprises the amino acid sequence of SEQ ID NO:68, or an amino acid sequence that is at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:68, and the VH comprises the amino acid sequence of SEQ ID NO:60, or an amino acid sequence that is at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO:60; preferably, the VL comprises the amino acid sequence of any one of SEQ ID NOs:68-73, and the VH comprises the amino acid sequence of SEQ ID NO:
60.
4. The antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 3, wherein The antigen-binding protein targeting CD40 is a full-length antibody, comprising a light chain and a heavy chain; the light chain comprises a light chain constant region (CL), which is preferably a human antibody light chain constant region, and more preferably a κ subtype light chain constant region; the heavy chain comprises a heavy chain constant region (CH), which is preferably a human antibody heavy chain constant region, and more preferably a hIgG1, hIgG2, hIgG3, or hIgG4 subtype heavy chain constant region, and further preferably a hIgG1 subtype heavy chain constant region; Preferably, the antigen-binding protein targeting CD40 is a full-length antibody, comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence as shown in any one of SEQ ID NOs: 87-92, and the heavy chain comprises the amino acid sequence as shown in SEQ ID NO: 78 or 84; more preferably, the light chain comprises the amino acid sequence as shown in SEQ ID NO: 87, and the heavy chain comprises the amino acid sequence as shown in SEQ ID NO: or, the light chain comprises the amino acid sequence as shown in any one of SEQ ID NOs: 88-92, and the heavy chain comprises the amino acid sequence as shown in SEQ ID NO:
84.
5. The antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 4, characterized in that The antigen-binding protein targeting PD-L1 comprises a heavy chain variable region (VH), wherein the VH comprises HCDR1, HCDR2, and HCDR3, wherein the HCDR1 comprises the amino acid sequence as shown in SEQ ID NO: 5 or a variant 7 having 3, 2, or 1 amino acid mutations in SEQ ID NO: 5, the HCDR2 comprises the amino acid sequence as shown in SEQ ID NO: 16 or a variant 8 having 3, 2, or 1 amino acid mutations in SEQ ID NO: 16, and the HCDR3 comprises the amino acid sequence as shown in SEQ ID NO: 25 or a variant 9 having 3, 2, or 1 amino acid mutations in SEQ ID NO: 25; preferably, the variant 7 is an amino acid sequence in which an amino acid mutation occurs at position 3 and / or position 6 of SEQ ID NO: 5, the variant 8 is an amino acid sequence in which an amino acid mutation occurs at position 1, position 3, and / or position 6 of SEQ ID NO: 16, and the variant 9 is an amino acid sequence in which an amino acid mutation occurs at position 1, position 3, and / or position 6 of SEQ ID NO: An amino acid sequence in which an amino acid mutation occurs at position 4, 8 and / or 11 of SEQ ID NO: 25, wherein the amino acid mutation is preferably an amino acid substitution, more preferably a conservative amino acid substitution; more preferably, the variant 7 is an amino acid sequence in which N3T / D and / or N5S mutations occur in SEQ ID NO: 5, the variant 8 is an amino acid sequence in which W1R, D3T and / or K5E mutations occur in SEQ ID NO: 16, and the variant 9 is an amino acid sequence in which I4L, V8I and / or A11D mutations occur in SEQ ID NO: 25; further preferably, the variant 7 is the amino acid sequence as shown in SEQ ID NO: 7 or 9, the variant 8 is the amino acid sequence as shown in SEQ ID NO: 19, and the variant 9 is the amino acid sequence as shown in SEQ ID NO: 28, 29 or 30.
6. The antigen binding protein targeting PD-L1 and CD40 according to claim 5, characterized in that In the antigen-binding protein targeting PD-L1, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 5, 7 or 9, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 16 or 19, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 25, 28, 29 or 30; preferably, in the antigen-binding protein targeting PD-L1, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 5, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 16, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 25; or, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 7, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 16, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 25; or, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: 7, the HCDR2 comprises the amino acid sequence shown in SEQ ID NO: 19, and the HCDR3 comprises the amino acid sequence shown in SEQ ID NO: 28; or, the HCDR1 comprises the amino acid sequence shown in SEQ ID NO: NO:9, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:19, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:25; or, the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:9, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:19, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:29; or, the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:9, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:19, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:30; or, the HCDR1 comprises the amino acid sequence set forth in SEQ ID NO:9, the HCDR2 comprises the amino acid sequence set forth in SEQ ID NO:19, and the HCDR3 comprises the amino acid sequence set forth in SEQ ID NO:
28.
7. The antigen binding protein targeting PD-L1 and CD40 according to claim 5 or 6, characterized in that In the antigen binding protein targeting PD-L1, the VH comprises the amino acid sequence as shown in SEQ ID NO: 57, or an amino acid sequence that is at least 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 57; preferably, the VH comprises the amino acid sequence as shown in any one of SEQ ID NOs: 57-65.
8. The antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 7, characterized in that The first protein functional region is an immunoglobulin comprising the antigen binding protein targeting CD40, and the second protein functional region comprises one, two or more VHs of the antigen binding protein targeting PD-L1; Preferably, the VH of the antigen binding protein targeting PD-L1 is directly linked to the immunoglobulin; or, the VH is linked to the immunoglobulin via a linker; or, when the number of the VH is greater than 1, each VH can be linked to the immunoglobulin directly or via a linker. More preferably, when the VH is connected to the immunoglobulin via a linker, the linker is selected from GS, GGS and any one of the amino acid sequences shown in SEQ ID NOs: 100-106.
9. The antigen binding protein targeting PD-L1 and CD40 according to claim 8, characterized in that The second protein functional region comprises the VHs of two antigen-binding proteins targeting PD-L1; preferably, the two VHs comprised in the second protein functional region are identical; and / or, the C-termini of the two VHs are respectively connected to the N-termini of the two heavy chains in the immunoglobulin via a linker such as GGS or SEQ ID NO:
5.
10. The antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 9, characterized in that The first protein functional region comprises two light chains comprising the amino acid sequence shown in any one of SEQ ID NOs: 88-92 and two heavy chains comprising the amino acid sequence shown in SEQ ID NO: 84; the second protein functional region comprises two VHs comprising the amino acid sequence shown in any one of SEQ ID NOs: 79-83, and the two VHs are connected at their C-termini to the N-termini of the two heavy chains in the first protein functional region via a linker such as GGS or SEQ ID NO: 5; Preferably, the antigen binding protein targeting PD-L1 and CD40 comprises a first polypeptide chain and a second polypeptide chain as shown below: The second polypeptide chain of SEQ ID NO:89 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:94; or the second polypeptide chain of SEQ ID NO:91 and the first polypeptide chain of SEQ ID NO:94; or the second polypeptide chain of SEQ ID NO:90 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:92 and the first polypeptide chain of SEQ ID NO:93; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:95; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:96; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:97; or the second polypeptide chain of SEQ ID NO:88 and the first polypeptide chain of SEQ ID NO:98; NO:91, and the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:95; or, the second polypeptide chain with an amino acid sequence as shown in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:93; or, the second polypeptide chain with an amino acid sequence as shown in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:96; or, the second polypeptide chain with an amino acid sequence as shown in SEQ ID NO:89, and the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:97; or, the second polypeptide chain with an amino acid sequence as shown in SEQ ID NO:90, and the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:97; or, the second polypeptide chain with an amino acid sequence as shown in SEQ ID NO:88 The second polypeptide chain, the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:98; or, the second polypeptide chain with an amino acid sequence as shown in SEQ ID NO:88, and the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:99; or, the second polypeptide chain with an amino acid sequence as shown in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:98; or, the second polypeptide chain with an amino acid sequence as shown in SEQ ID NO:91, and the first polypeptide chain with an amino acid sequence as shown in SEQ ID NO:
99.
11. A chimeric antigen receptor, characterized in that It comprises the antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10.
12. An isolated nucleic acid, characterized in that The isolated nucleic acid encodes the antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10.
13. A recombinant expression vector, characterized in that: The recombinant expression vector comprises the isolated nucleic acid according to claim 12; preferably, the recombinant expression vector comprises a eukaryotic cell expression vector and / or a prokaryotic cell expression vector.
14. A transformant, characterized in that The transformant comprises the isolated nucleic acid according to claim 12 or the recombinant expression vector according to claim 13; preferably, the host cell of the transformant is a prokaryotic cell and / or a eukaryotic cell, the prokaryotic cell is preferably an E. coli cell such as TG1, BL21, and the eukaryotic cell is preferably a HEK293 cell or a CHO cell.
15. A method for preparing an antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10, characterized in that: The preparation method comprises the following steps: culturing the transformant according to claim 14, and obtaining the antigen-binding protein targeting PD-L1 and CD40 from the culture.
16. An antibody-drug conjugate, characterized in that: The antibody-drug conjugate comprises the antigen-binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10, and a cytotoxic agent or a label; preferably, the cytotoxic agent is MMAF or MMAE, and the label is a fluorescent agent.
17. A genetically modified cell, characterized in that The genetically modified cells express the chimeric antigen receptor as described in claim 11; preferably, the genetically modified cells are eukaryotic cells, preferably isolated human cells, and more preferably immune cells such as T cells or NK cells.
18. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises one or more of the antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10, the chimeric antigen receptor according to claim 11, the isolated nucleic acid according to claim 12, the recombinant expression vector according to claim 13, the genetically modified cell according to claim 17, and the antibody-drug conjugate according to claim 16, and / or a pharmaceutically acceptable carrier; preferably, the pharmaceutical composition further comprises other anti-tumor drugs as active ingredients, and the anti-tumor drugs include but are not limited to: chemotherapy drugs, nucleotide drugs, small molecule targeted drugs, monoclonal antibody drugs, bi / multi-specific antibody drugs, recombinant protein drugs, immunomodulatory drugs, cell therapy drugs and gene therapy drugs.
19. A detection reagent, characterized in that The detection reagent comprises the antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10 and / or the antibody-drug conjugate according to claim 16; preferably, the detection reagent is in liquid dosage form, gaseous dosage form, solid dosage form and semi-solid dosage form; more preferably, the detection reagent further comprises a secondary antibody, CD40 or a derivative thereof, the secondary antibody, for example, an anti-human IgG antibody coupled to horseradish peroxidase and an anti-human IgG antibody coupled to biotin protein.
20. A medicine kit, characterized in that: The kit comprises kit A, which contains one or more of the antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10, the chimeric antigen receptor according to claim 11, the pharmaceutical composition according to claim 18, the detection reagent according to claim 19, the genetically modified cell according to claim 17, and the antibody-drug conjugate according to claim 16; Preferably, the kit further comprises a kit B, which contains other anti-tumor antibodies or pharmaceutical compositions comprising the other anti-tumor antibodies, and / or one or more of a group consisting of hormone preparations, targeted small molecule preparations, proteasome inhibitors, imaging agents, diagnostic agents, chemotherapeutic agents, oncolytic drugs, cytotoxic agents, cytokines, activators of co-stimulatory molecules, inhibitors of inhibitory molecules, and vaccines. 21.Use of one or more of the antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10, the chimeric antigen receptor according to claim 11, the isolated nucleic acid according to claim 12, the recombinant expression vector according to claim 13, the pharmaceutical composition according to claim 18, the detection reagent according to claim 19, the kit according to claim 20, the genetically modified cell according to claim 17, and the antibody-drug conjugate according to claim 16 in the preparation of a drug for diagnosing, preventing and / or treating PD-L1 and / or CD40-related diseases; preferably, the PD-L1 and / or CD40 related diseases are PD-L1 related tumors, CD40 related tumors or PD-L1×CD40 related tumors, the CD40 related tumors include solid tumors and blood tumors, the PD-L1 related tumors include solid tumors and blood tumors; more preferably, the CD40 related tumors include B-lineage NHL, chronic lymphocytic leukemia (CLL), hairy cell leukemia (HCL), Hodgkin's disease, multiple myeloma, bladder cancer, kidney cancer, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal cancer, malignant melanoma, pancreatic cancer and colon cancer, the PD-L1 related tumors include squamous cell carcinoma, bone marrow cancer, leukemia, ovarian cancer, cervical cancer, breast cancer, lung cancer, nasopharyngeal cancer, malignant melanoma, pancreatic cancer and colon cancer, Myeloma, small cell lung cancer, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), glioma, Hodgkin lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), primary mediastinal large B-cell lymphoma, mantle cell lymphoma (MCL), small lymphocytic lymphoma (SLL), T-cell / histiocyte-rich large B-cell lymphoma, multiple myeloma tumors, myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), gastrointestinal cancer, kidney cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, stomach cancer, bone cancer, Ewing's sarcoma, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon cancer, hepatocellular carcinoma (HCC), clear cell renal cell carcinoma (RCC), head and neck cancer, pharyngeal cancer, hepatobiliary cancer cancer), central nervous system cancer, esophageal cancer, malignant pleural mesothelioma, systemic light chain amyloidosis, lymphoplasmacytic lymphoma, myelodysplastic syndrome, myeloproliferative neoplasms, neuroendocrine tumors, Merkel cell carcinoma, testicular cancer and skin cancer, preferably colon cancer with high PD-L1 expression.
22. A method for detecting PD-L1 and / or CD40 in a sample, characterized in that: The method comprises the step of contacting the sample with one or more of the antigen-binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10, the detection reagent according to claim 19, and the antibody-drug conjugate according to claim 16; the sample is, for example, a blood sample (e.g., a whole blood sample and a serum sample) and a reagent containing PD-L1 and / or CD40; preferably, the method is for non-therapeutic / diagnostic purposes.
23. A method for diagnosing, treating and / or preventing a PD-L1 and / or CD40-related disease, the method comprising administering to a patient in need thereof a therapeutically effective amount of one or more of the antigen binding protein targeting PD-L1 and CD40 according to any one of claims 1 to 10, the chimeric antigen receptor according to claim 11, the isolated nucleic acid according to claim 12, the recombinant expression vector according to claim 13, the pharmaceutical composition according to claim 18, the detection reagent according to claim 19, the kit according to claim 20, the genetically modified cell according to claim 17, and the antibody-drug conjugate according to claim 16; preferably, the PD-L1 and / or CD40-related disease is a PD-L1-related tumor, a CD40-related tumor, or a PD-L1×CD40-related tumor.
Citation Information
Cited By
Single-domain antibody 14-D3 targeting cross binding of human and cynomolgus monkey PD-L1 and application of single-domain antibody 14-D3
CN122187981A
A single-domain antibody 14-d3 targeting human and cynomolgus pd-l1 cross-binding and applications thereof
CN122187981B
